

# KSGO International Conference 2025

The 40th Annual Meeting of  
Korean Society of Gynecologic Oncology

April 25 (Fri)-26 (Sat), 2025  
ST Center, Seoul, Korea

*"Breaking barriers, Building bridges"*



Korean Society of Gynecologic Oncology





# NO COMPARISON Original Paclitaxel, TAXOL

탁솔주는 국내외 임상 연구를 통해  
효과와 안전성을 확인한 **오리지널 파클리탁셀** 제품입니다.<sup>1,2</sup>

## PRODUCT INFORMATION

### 탁솔주 (Taxol inj.)

**【성분/함량】** Paclitaxel 파클리탁셀 30mg/5mL **【성상】** 무색의 바이알에 들어있는 무색 또는 미황색의 점성이 있는 맑은 주사액 **【효능·효과】** 이 약은 난소암, 유방암, 폐암 또는 위암의 치료에 단독으로 혹은 병용하여 사용된다. 1) 난소암 (1) 다른 화학요법제와 병용하여 1차 요법제로 사용 (2) 표준 요법에 실패한 전이성 난소암의 치료에 2차 요법제로 사용 2) 유방암 (1) 표준요법에 실패한 전이성 유방암의 치료에 2차 요법제로 사용 (2) 결절 양성 유방암의 보조치료. 표준 독소루비신 함유 병용 화학요법 후 사용 (3) HER2(Human Epidermal growth factor Receptor 2 protein)가 과발현(IHC 3+ 또는 FISH 양성)되고 화학요법 치료를 받은 경험이 없는 전이성 유방암에 트라스투주맙과 병용 요법제로 사용 3) 폐암 : 진행성 비소세포 폐암의 치료에 1차 요법제로 사용 4) 위암 : 진행성 및 전이성 또는 국소 재발성 위암 **【용법·용량】** 제품설명서 참조 **【사용상의 주의사항】** 제품설명서 참조 참조 **【저장방법】** 차광보관 밀봉용기 15-30°C 보관 **【포장단위】** 5mL/바이알 x 10바이알 **【판매처】** (주)보령-서울시 중로구 장경궁로 136 보령빌딩  
※ 기타 자세한 내용은 제품설명서를 참고하시기 바랍니다.

1. Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

2. A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)

# CONTENTS

Welcome Message	03
KSGO Executive Directors	04
Program at a Glance	08
Lecture Materials (QR Code)	10
Scientific Programs Day 1	14
Scientific Programs Day 2	30
E-Poster Exhibition	48
Surgical Film Screening	55
Congress Information	58
Floor Plan	65
Acknowledgements	68





**Korean Society of Gynecologic Oncology**



## WELCOME MESSAGE

Dear Esteemed Colleagues

On behalf of the Korean Society of Gynecologic Oncology (KSGO), it is my great honor and privilege to welcome you to the KSGO 2025 International Conference, which will take place in April 2025. This year's meeting is particularly significant as we celebrate 40 years of KSGO's history and embark on a new journey with our inaugural international conference.

The theme for this historic event, "Breaking Barriers, Building Bridges," reflects our commitment to advancing the field of gynecologic oncology by transcending boundaries -whether scientific, clinical, or geographical- and fostering global collaboration.

This meeting will highlight innovative approaches to ovarian cancer surgery, presenting diverse surgical techniques and introducing a new paradigm in treatment and care. We aim to inspire meaningful discussions and exchange of ideas that will shape the future of gynecologic oncology.

In addition, we are excited to collaborate with partner societies from neighboring countries, hosting joint sessions to strengthen our ties within the region and enhance community engagement. Through this shared platform, we hope to create opportunities for mutual growth and closer cooperation.

I sincerely invite you to join us in this groundbreaking endeavor. Together, let us explore, learn, and contribute to the advancement of gynecologic oncology. Your active participation and valuable insights will undoubtedly make this conference a memorable and impactful experience.

Thank you, and I look forward to welcoming you in April 2025.

Warm regards,



**Jae-Kwan LEE**

President

Korean Society of Gynecologic Oncology



## KSGO EXECUTIVE DIRECTORS

### Core Officers

#### President

**Jae-Kwan Lee**  
Korea University

#### Vice President

**Suk-Joon Chang**  
Ajou University

#### Vice President

**Sang-Hoon Kwon**  
Keimyung University

#### Vice President

**Seob Jeon**  
Soonchunhyang University

#### Secretary General

**Kyung-Jin Min**  
Korea University

#### Deputy Secretary General

**Tae-Wook Kong**  
Ajou University

#### Auditor

**Tae Gyu Ahn**  
Chosun University

#### Auditor

**Seok Ju Seong**  
CHA University

### Council Member

#### Director of Publication Committee

**Eunji Nam**  
Yonsei University

#### Director of Judging Committee

**Kwang-Beom Lee**  
Gachon University

#### Director of Planning Committee

**Sunghoon Kim**  
Yonsei University

#### Vice Director of Planning Committee

**Sojin Shin**  
Keimyung University

#### Director of Finance Committee

**Chel Hun Choi**  
Sungkyunkwan University

#### Director of Insurance Committee

**Jae Hong No**  
Seoul National University

#### Director of Advertising Committee

**Taek Sang Lee**  
Seoul National University

#### Vice Director of Advertising Committee

**Eun-Ju Lee**  
Chung-Ang University

#### Director of Legislation Committee

**Chul Min Park**  
Jeju National University

#### Director of Ethics Committee

**Dae Hoon Jeong**  
Inje University

#### Director of International Relation Committee

**Yoo Young Lee**  
Sungkyunkwan University

#### Vice Director of International Relation Committee

**Ga Won Yim**  
Dongguk University

#### Director of Information and Communication Committee

**Banghyun Lee**  
Inha University

#### Director of Training Committee

**Sung-Jong Lee**  
The Catholic University of Korea

#### Director of Treatment Guideline Committee

**Jaeman Bae**  
Hanyang University

#### Vice Director of Treatment Guideline Committee

**Seung-Hyuk Shim**  
Konkuk University



Director of Gynecologic Cancer Prevention Committee

**Woong Ju**

Ewha Womans University

Director of Research Subcommittee

**Jeong-Yeol Park**

University of Ulsan

Director of Editorial Publication Subcommittee

**Sang Hoon Lee**

Korea University

Director of Conflict of Interest (COI) Subcommittee

**Shin-Wha Lee**

University of Ulsan

Director of Hereditary Gynecologic Cancer Subcommittee

**Myong Cheol Lim**

National Cancer Center

Director of Nursing Subcommittee

**Young Soo Chu**

Korea University Anam Hospital

Vice Director of Gynecologic Cancer Prevention Committee

**Woo Dae Kang**

Chonnam National University

Director of Newsletter Subcommittee

**Gun Oh Chong**

Kyungpook National University

Director of Gynecologic Cancer Registration Subcommittee

**Sokbom Kang**

National Cancer Center

Editor-in-chief of Journal of Gynecologic Oncology

**Dong Hoon Suh**

Seoul National University

Director of Subcommittee for Exchange with Related Societies

**Jae Yun Song**

Korea University

## Scientific Program Committee

Chair

**Suk-Joon Chang**

Ajou University

Secretary General

**Tae-Wook Kong**

Ajou University

Members

**Mi Kyung Kim**

Ewha Womans University

**Tae Hun Kim**

Seoul National University

**Sung Taek Park**

Hallym University

**Seung-Hyuk Shim**

Konkuk University

**Yoo Young Lee**

Sungkyunkwan University

**Ga Won Yim**

Dongguk University

**Min Chul Choi**

University of Ulsan

**Ji Hyun Kim**

National Cancer Center

**Jee Yeon Kim**

Ajou University

**Eunji Nam**

Yonsei University

**Sojin Shin**

Keimyung University

**Shin-Wha Lee**

University of Ulsan

**Heon Jong Yoo**

Chungnam National University

**Jae Yun Song**

Korea University

**Youn Jin Choi**

The Catholic University of Korea

**Soo Hyun Oh**

Gachon University

## KSGO EXECUTIVE DIRECTORS

### Board of Directors

**Soon Beom Kang**  
Hosan Women's Hospital

**Kyung Tai Kim**  
Hanyang University

**Ki Tae Kim**  
Inje University

**Seokmo Kim**  
Chonnam National University

**Sungyob Kim**  
Jeju National University

**Soo-Nyung Kim**  
Konkuk University

**Seung-Jo Kim**  
CHA University

**Seung Cheol Kim**  
Ewha Womans University

**Young Tak Kim**  
CHA University

**Young Tae Kim**  
Yonsei University

**Yong Man Kim**  
University of Ulsan

**Yong Beom Kim**  
Seoul National University

**Won Gyu Kim**  
Kosin University

**Jae-Wook Kim**  
Yonsei University

**Jae-Weon Kim**  
Seoul National University

**Jae-Hoon Kim**  
Yonsei University

**Tae Jin Kim**  
Konkuk University

**Hak Soon Kim**  
Chungbuk National University

**Hong Bae Kim**  
Hayllm University

**Kyehyun Nam**  
Soonchunhyang University

**Sung-Eun Namkoong**  
The Catholic University of Korea

**Joo-Hyun Nam**  
University of Ulsan

**Ki-Sung Ryu**  
The Catholic University of Korea

**Jung-Eun Mok**  
University of Ulsan

**Noh Hyun Park**  
Seoul National University

**Sang Yoon Park**  
National Cancer Center

**Jong Sup Park**  
The Catholic University of Korea

**Jong Taeg Park**  
CHA University

**Chan Kyu Park**  
Yonsei University

**Duk-Soo Bae**  
Sungkyunkwan University



**Yong Sang Song**  
Seoul National University

**Jae Uk Shim**

**Jae Chul Sim**  
Dongguk University

**Byung Chan Oh**  
Jeonbuk National University

**Sang Young Ryu**  
Korea Cancer Center Hospital

**Hee-Sug Ryu**  
Ajou University

**Mansoo Yoon**  
Busan National University

**Kyu Wan Lee**  
Korea University

**Nak Woo Lee**  
Korea University

**Seon-kyung Lee**  
CHA University

**Yoon Soon Lee**  
Kyungpook University

**Eung Soo Lee**  
Inje University

**Jae Kwan Lee**  
Korea University

**Jeong-Won Lee**  
Sungkyunkwan University

**Jong-Min Lee**  
Kyunghee University

**Jong Hak Lee**  
Gyeongsang National University

**Joon Mo Lee**  
The Catholic University of Korea

**Chulmin Lee**  
CHA University

**Taesung Lee**  
Daegu Catholic University

**Hyo Pyo Lee**  
Soonchunhyang University

**Suk-Joon Chang**  
Ajou University

**Young Rae Cho**  
Kyungpook University

**Chi-Heum Cho**  
Keimyung University

**Soon Do Cha**  
Keimyung University


**Joong Sub Choi**  
Hanyang University

**Hosun Choi**  
Chonnam National University

**Se Jun Han**  
Chosun University

**Sooyoung Hur**  
The Catholic University of Korea

## PROGRAM AT A GLANCE Day 1: April 25 (Fri), 2025

Room	Hall A	Hall B	Hall C	Hall D
08:00-08:30	Registration			
08:30-09:00	Best Oral Presentation			E-Poster Exhibition & Surgical Film Screening
09:00-09:30				
09:30-10:00	Opening Ceremony Group Photo			
10:00-10:30	Scientific Session I			
10:30-11:00				
11:00-11:30		11:00-12:00 Collaborative Session I -JSGO		
11:30-12:00				
12:00-12:30	Coffee Break			
12:30-13:00	12:20-12:50 Industry Session I BORYUNG	12:20-12:50 Industry Session II  MSD	12:20-12:50 Industry Session III inno.N	
13:00-13:30	13:00-14:00 Collaborative Session II -CSGO	13:00-14:00 Collaborative Session III -INASGO	13:00-13:40 Mini-Oral I	
13:30-14:00				
14:00-14:30	Coffee Break			E-Poster Session
14:30-15:00	Live Surgery			E-Poster Exhibition & Surgical Film Screening
15:00-15:30				
15:30-16:00			15:00-17:05 Collaborative Session IV -AOGIN	
16:00-16:30				
16:30-17:00				
17:00-17:30				
17:30-18:30				
18:30-20:00	Gala Dinner [Novotel Ambassador Seoul Gangnam-Champagne Hall]			








## PROGRAM AT A GLANCE Day 2: April 26 (Sat), 2025











Room	Hall A	Hall B	Hall C	Hall D
07:30-08:00	Registration		07:30-08:30	Registration
08:00-08:30			JGO PE Meeting (Closed)	
08:30-09:00	08:00-08:40 Industry Session VII 		08:30-09:30	E-Poster Exhibition & Surgical Film Screening
09:00-09:30			JGO Workshop (International)	
09:30-10:00	09:30-11:30 Scientific Session II	09:30-10:30		
10:00-10:30		Collaborative Session V -TGCS	10:00-10:40 Mini-Oral II	
10:30-11:00		10:30-11:30	10:40-11:20 Mini-Oral III	
11:00-11:30		Collaborative Session VI -TAGO		
11:30-12:00	Coffee Break			
12:00-12:30	11:50-12:20 Industry Session IV GSK	11:50-12:20 Industry Session V 	11:50-12:20 Industry Session VI 	
12:30-13:00	Lunch Break			
13:00-13:30	12:50-14:20	12:50-14:20	12:50-14:20	
13:30-14:00	Tumor Board	Collaborative Session VII -KGOG	Young Investigator Session	
14:00-14:30	Coffee Break			
14:30-15:00	14:40-16:10	14:40-16:10	14:40-16:00	
15:00-15:30	Debate Session	Collaborative Session VIII -KGCR	Nursing Session (Kor.)	
15:30-16:00				
16:00-16:40	16:10-16:40	Lucky Draw & Closing Address		

## LECTURE MATERIALS (QR Code)

Please scan the QR code located at the bottom to download the lecture materials.

### DAY 1 - April 25 (Fri)

Program	Scan to QR Code
Best Oral Presentation	
	
Abstract	Slide
Scientific Session I	
	
Abstract	Slide
Collaborative Session I-JSGO	
	
Abstract	Slide
Collaborative Session II-CSGO	
	
Abstract	Slide
Collaborative Session III-INASGO	
	
Abstract	Slide
Collaborative Session IV - AOGIN	
	
Abstract	Slide
Live Surgery	
	
Abstract	
Abstract	
	
















Program	Scan to QR Code
Industry Session I -BORYUNG	
	
Abstract	Slide
Industry Session II - MSD	
	
Abstract	Slide
Industry Session III – HK inno.N	
	
Abstract	Slide
Mini Oral I	
	
Abstract	Slide
E-Poster Session	
	
Abstract	
E-Poster Exhibition	
	
Abstract	
Surgical Film Screening	
	
Abstract	
Slide	
	



















## LECTURE MATERIALS (QR Code)

Please scan the QR code located at the bottom to download the lecture materials.

### DAY 2 - April 26 (Sat)

Program	Scan to QR Code
JGO Workshop	
	
Abstract	Slide
Scientific Session II	
	
Abstract	Slide
Debate Session	
	
Abstract	Slide
Tumor Board	
	
Abstract	
Collaborative Session V-TGCS	
	
Abstract	Slide
Collaborative Session VI-TAGO	
	
Abstract	Slide
Collaborative Session VII-KGOG	
	
Abstract	Slide
Collaborative Session VIII-KGCR	
	
Abstract	Slide

Program	Scan to QR Code
Industry Session IV-GSK	
	
Abstract	Slide
Industry Session V-Takeda	
	
Abstract	Slide
Industry Session VI-Roche Diagnostics	
	
Abstract	Slide
Industry Session VII-Chong Kun Dang	
	
Abstract	Slide
Mini-Oral II	
	
Abstract	Slide
Mini-Oral III	
	
Abstract	Slide
Young Investigator Session	
	
Abstract	Slide
Nursing Session (Kor.)	
	
Abstract	Slide



**Korean Society of Gynecologic Oncology**

# KSGO International Conference 2025

The 40th Annual Meeting of  
Korean Society of Gynecologic Oncology

---

## SCIENTIFIC PROGRAMS DAY 1

Best Oral Presentation  
Opening Ceremony  
Scientific Session I (Ovarian Cancer)  
Collaborative Session: JSGO  
Industry Session I - BORYUNG  
Industry Session II - MSD  
Industry Session III - HK inno.N  
Collaborative Session: CSGO  
Collaborative Session: INASGO  
Mini-Oral I  
E-poster Session  
Live Surgery  
Collaborative Session: AOGIN



## • April 25 (Friday)

08:30-09:30	Best Oral Presentation	Hall A/B/C
Chair(s)	Sooyoung Hur (The Catholic University of Korea), Jeong-Won Lee (Sungkyunkwan University)	
08:30-08:40	<b>Impact of neoadjuvant chemotherapy (NAC) combined with durvalumab and tremelimumab on the tumour immune microenvironment in advanced ovarian cancer: translational analyses from the TRU-D/KGOG 3046 study</b> Junsik Park (Soonchunhyang University)	
08:40-08:45	<b>Designated discussion</b> Taehun Kim (Seoul National University)	
08:45-08:55	<b>Integrative spatial and transcriptomic profiling reveals novel prognostic clusters in cervical cancer</b> Jong Mi Kim (Kyungpook National University)	
08:55-09:00	<b>Designated discussion</b> Eun Bi Jang (Konkuk University)	
09:00-09:10	<b>A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)</b> Yong Jae Lee (Yonsei University)	
09:10-09:15	<b>Designated discussion</b> Soo Hyun Oh (Gachon University)	
09:15-09:25	<b>Utility of the CA125 KELIM in for predicting the Benefit of from HIPEC in patients with advanced ovarian cancer: Pooled analysis of Individual data from KGOG3042 and KOV-HIPEC-01</b> Hyun-Woong Cho (Korea University)	
09:25-09:30	<b>Designated discussion</b> Soo Young Jeong (Hallym University)	



## • April 25 (Friday)

09:30-10:00	<b>Opening Ceremony</b>  <b>Welcome Remark</b> Jae-Kwan Lee (President of KSGO)  <b>2025 - 2026 KSGO Board of Directors</b>  <b>2025 New Gynecologic Oncologist of KSGO</b> Eun Bi Jang (Konkuk University), Jimin Lee (Ajou University), Mia Park (Chungnam National University), Ji Hyun Lee (Yonsei University)	Hall A/B/C
09:30-10:00	<b>KSGO Appreciation Award</b> Jae-Weon Kim (Past President of KSGO), Hee Seung Kim (Past Secretary General of KSGO)  <b>KSGO Achievement Award</b> Suk-Joon Chang (KSGO 40th Anniversary Project Subcommittee Chair), Nam Kyeong Kim (KSGO 40th Anniversary Project Subcommittee Administrative Coordinator)  <b>Introduction of KSGO International Conference 2025</b> Suk-Joon Chang (Chair of Scientific Program Committee)  <b>Group Photo</b>	

## • April 25 (Friday)

10:00-11:30	<b>Scientific Session I (Ovarian Cancer)</b>	Hall A
Chair(s)	Young Tae Kim (Yonsei University), Yoichi Kobayashi (Kyorin University)	
10:00-10:20	<b>Role of secondary cytoreductive surgery for recurrent ovarian cancer in the era of PARPi</b> Christina Fotopoulou (Imperial College London)	
10:20-10:25	<b>Designated discussion</b> Hyeong In Ha (NHIC Ilsan Hospital)	
10:25-10:30	Floor discussion	
10:30-10:50	<b>Updated ovarian cancer trials in China</b> Rongyu Zang (Zhongshan Hospital)	
10:50-10:55	<b>Designated discussion</b> Shin-Wha Lee (University of Ulsan)	
10:55-11:00	Floor discussion	
11:00-11:20	<b>Next horizon in ovarian cancer: Evolving clinical trials and translational research</b> Jung-Yun Lee (Yonsei University)	
11:20-11:25	<b>Designated discussion</b> Sung Jong Lee (The Catholic University of Korea)	
11:25-11:30	Floor discussion	

## • April 25 (Friday)

11:00-12:00	<b>Collaborative Session: Current Status of Gynecologic Cancer Treatment in Japan (JSGO)</b>	Hall B
Chair(s)	Aikou Okamoto (Jikei University), Jae-Weon Kim (Seoul National University)	
11:00-11:15	<b>Cervical cancer</b> Hideki Tokunaga (Tohoku University)	
11:15-11:20	<b>Designated discussion</b> Eun Ji Nam (Yonsei University)	
11:20-11:35	<b>Endometrial cancer</b> Tohru Morisada (Kyorin University)	
11:35-11:40	<b>Designated discussion</b> Banghyun Lee (Inha University)	
11:40-11:55	<b>Ovarian cancer</b> Tsukasa Baba (Iwate Medical University)	
11:55-12:00	<b>Designated discussion</b> Sang Hun Lee (University of Ulsan)	

## • April 25 (Friday)

12:20-12:50	<b>Industry Session I</b> BORYUNG	Hall A
Chair(s)	Taek Sang Lee (Seoul National University)	
12:20-12:40	<b>Latest knowledge of 2nd generation G-CSF in gynecological cancer (Neulasta)</b> Joseph Noh (Seoul National University)	
12:40-12:50	Floor discussion	

## • April 25 (Friday)

12:20-12:50	<b>Industry Session II</b>  MSD	Hall B
Chair(s)	Sang Wun Kim (Yonsei University)	
12:20-12:40	<b>Breaking endometrial cancer, building a patient's life: The role of pembrolizumab in both pMMR and dMMR (KEYNOTE-868/NRG-GY018)</b> Yoo-Young Lee (Sungkyunkwan University)	
12:40-12:50	Floor discussion	



## • April 25 (Friday)

12:20-12:50	<b>Industry Session III</b> <a href="#">inno.N</a>	Hall C
Chair(s)	Sokbom Kang (National Cancer Center)	
12:20-12:40	<b>The optimal treatment strategy for front-line ovarian cancer management</b> Hyung Joon Yoon (Pusan National University)	
12:40-12:50	Floor discussion	

## • April 25 (Friday)

13:00-14:00	<b>Collaborative Session: Current Status of Gynecologic Cancer Treatment in China (CSGO)</b>	Hall A
Chair(s)	Beihua Kong (Qilu Hospital of Shandong University), Jae-Kwan Lee (Korea University)	
13:00-13:15	<b>The laparoscopic surgery for early stage of cervical cancer: What is the future?</b> Yang Xiang (Peking Union Medical Center Hospital)	
13:15-13:20	<b>Designated discussion</b> Seung Hyuk Shim (Konkuk University)	
13:20-13:35	<b>The fertility sparing treatment for endometrium cancer in China</b> Yiqin Wang (Peking University People's Hospital)	
13:35-13:40	<b>Designated discussion</b> Jeong-Yeol Park (University of Ulsan)	
13:40-13:55	<b>Ovarian cancer trials in China</b> Rongyu Zang (Zhongshan Hospital)	
13:55-14:00	<b>Designated discussion</b> Jae Yun Song (Korea University)	

## • April 25 (Friday)

13:00-14:00	<b>Collaborative Session: Current Status of Gynecologic Cancer Treatment in Indonesia (INASGO)</b>	Hall B
Chair(s)	Yudi Mulyana Hidayat (Hasan Sadikin General Hospital Bandung), Tae-Wook Kong (Ajou University)	
13:00-13:15	<b>Epidemiology of gynecologic cancer in Indonesia: Shifting cancer burden to the young population</b> Yudi Mulyana Hidayat (Hasan Sadikin General Hospital Bandung)	
13:15-13:20	<b>Designated discussion</b> Heon Jong Yoo (Chungnam National University)	
13:20-13:35	<b>Optimizing gynecologic cancer management in Indonesia: Addressing disparities and enhancing surgical skills</b> Brahmana Askandar (Airlangga University)	
13:35-13:40	<b>Designated discussion</b> San Hui Lee (Yonsei University Wonju)	
13:40-13:55	<b>Future directions in diagnostics and therapy for gynecologic cancer in Indonesia: Implementing molecular testing and targeted therapies</b> Tricia Dewi Angggraeni (Universitas Indonesia)	
13:55-14:00	<b>Designated discussion</b> Hyunji Lim (Seoul National University)	

## • April 25 (Friday)

13:00-13:40	Mini-Oral I	Hall C
Chair(s)	Yong Beom Kim (Seoul National University), Dong Choon Park (The Catholic University of Korea)	
13:00-13:04	<b>Characterization of humanized mouse model for evaluating immunotherapy in ovarian cancer</b> Sung Wan Kang (Asan Medical Center)	
13:04-13:08	Discussion	
13:08-13:12	<b>Is consolidation therapy effective in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment?</b> Eun Bi Jang (Konkuk University)	
13:12-13:16	Discussion	
13:16-13:20	<b>Microbial metabolites control self-renewal and precancerous progression of human cervical stem cells</b> Hee Yeun Yoon (Kyungpook National University)	
13:20-13:24	Discussion	
13:24-13:28	<b>Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: a phase III, double-blind, randomized study</b> Hee Seung Kim (Seoul National University)	
13:28-13:32	Discussion	
13:32-13:36	<b>Clinical impact of first-line maintenance therapy agents on survival outcomes in ovarian cancer patients stratified by homologous recombination status</b> Young Joo Lee (Kyung Hee University)	
13:36-13:40	Discussion	

## • April 25 (Friday)

13:40-14:30	E-poster Session			Hall D
Chair(s)	Line 1 - Dae Hoon Jeong (Inje University)	Line 2 - Gun Oh Chong (Kyungpook National University)	Line 3 - Eun-Ju Lee (Chung-Ang University)	
13:40-13:45	<b>Effects of metabolic risk score on treatment decision for endometrial cancer: establishment of a machine learning-based predictive model for survival</b> Jingyuan Wang (Peking University)	<b>Does HRD score predict response and survival outcomes to platinum-based neoadjuvant chemotherapy?</b> Uisuk Kim (National Cancer Center)	<b>Oregovomab in combination with non-platinum chemotherapy for the treatment of PARP inhibitor- and platinum-resistant ovarian cancer: a two-cohort, single-arm phase 2 study (OPERA/ KGOG3065/APGOT-OV6)</b> Junsik Park (Soonchunhyang University)	
13:45-13:47	Discussion	Discussion	Discussion	
13:47-13:52	<b>vNOTES hysterectomy with sentinel node dissection</b> Edvard Berg (Bashkir State Medical University)	<b>Prognosis of patients who become pregnancy after achieving a complete response with fertility-sparing treatment in early endometrial cancer: Gynecologic oncology research investigators coLLaborAtion study (GORILLA-3001)</b> A Jin Lee (CHA University)	<b>Outcomes of laparoscopic resection for pelvic recurrence of endometrial cancer: A single-center retrospective study</b> Risako Ozawa (Cancer Institute Hospital of JFCR)	
13:52-13:54	Discussion	Discussion	Discussion	
13:54-13:59	<b>Surgical indications for residual and recurrent cervical cancer after radiation therapy</b> Mayumi Kamata (Cancer Institute Hospital of JFCR)	<b>Prognostic impact of primary surgery in human papillomavirus-independent, advanced or metastatic endocervical adenocarcinoma: A bi-institutional retrospective study</b> Jun-Hyeong Seo (Sungkyunkwan University)	<b>Landscape of genomic alterations and clinical outcomes in low-grade serous ovarian cancer in Korea</b> Ji Hyun Kim (National Cancer Center)	
13:59-14:01	Discussion	Discussion	Discussion	
14:01-14:06	<b>Challenges facing female gynecologic oncology professionals in their career development: Results from the survey of Asian countries</b> Ga Won Yim (Dongguk University)	<b>Postoperative early morbidity and mortality outcomes of primary and interval cytoreductive surgery for advanced epithelial ovarian cancer; A Korean gynecologic oncologic group (KGOG 4005/4006)</b> Heon Jong Yoo (Chungnam National University)	<b>Value of systematic lymphadenectomy in early stage, high grade epithelial ovarian cancer, in the era of modern imaging</b> Minah Ha (Auckland City Hospital)	
14:06-14:08	Discussion	Discussion	Discussion	



## • April 25 (Friday)

13:40-14:30	E-poster Session			Hall D
14:08-14:13	<b>Monocytes as potential predictors of immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors</b> Ayumi Shikama (University of Tsukuba)	<b>A domestic exchange program for gynecologic oncology doctors in Japan</b> Hiroko Matsumiya (Hokkaido University Hospital)	<b>Clinical significance of claudin 18 in gastric adenocarcinoma of the cervix</b> Fumimasa Osone (The Jikei University Hospital)	
14:13-14:15	Discussion	Discussion	Discussion	
14:15-14:20	<b>Clinical features' differences between CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors</b> Yana Ma (Qilu Hospital of Shandong University)	<b>Hyperthermia-Induced sensitization of cisplatin-resistant ovarian cancer cells: A potential strategy for overcoming drug resistance</b> Joo-Hyuk Son (Ajou University)	<b>Survival outcomes of postoperative chemotherapy versus concurrent chemoradiotherapy followed by chemotherapy in advanced endometrial cancer</b> Aeran Seol (Seoul National University)	
14:20-14:22	Discussion	Discussion	Discussion	
14:22-14:27	<b>Impact of primary radical surgery on survival outcomes in patients with locally advanced HPV-independent endocervical adenocarcinoma</b> Hyunji Lim (Seoul National University)	<b>GLDC promotes cisplatin resistance of ovarian cancer cells by enhancing ROS-driven mitochondrial fission</b> Seungmee Lee (Keimyung University)	<b>Pattern of care study for radiotherapy of recurrent ovarian cancer patients among gynecologic and radiation oncologists in Korea</b> Bo Ra Kim (Ewha Womans University)	
14:27-14:30	Discussion	Discussion	Discussion	

## • April 25 (Friday)

14:20-17:20	<b>Live Surgery-Ovarian Cancer</b>	Hall A
Chair(s)	Suk-Joon Chang (Ajou University), Christina Fotopoulou (Imperial College London), Yoo-Young Lee (Sungkyunkwan University)	
	<b>Primary cytoreductive surgery for ovarian cancer</b> Philipp Harter (Ev. Kliniken Essen-Mitte)	
14:20-17:20	<b>Interval cytoreductive surgery for ovarian cancer</b> Sang Yoon Park (National Cancer Center)	
	<b>Robot hybrid cytoreductive surgery</b> Myong Cheol Lim (National Cancer Center)	

## • April 25 (Friday)

15:00-17:05	<b>Collaborative Session: AOGIN</b>	Hall C
Chair(s)	Part 1: Current Issues in Cervical Cancer Screening and Management - Yong Man Kim (University of Ulsan)	
15:00-15:20	<b>Cervical cancer screening based on HPV test</b> Shin-Wha Lee (University of Ulsan)	
15:20-15:40	<b>Implementation of primary HPV screening and self-sampling in Thailand</b> Wichai Termrungruanglert (Chulalongkorn University)	
15:40-16:00	<b>The role of extended genotyping in cervical cancer elimination</b> Tessa Riandini (Becton, Dickinson and Company)	
16:00-16:10	Discussion	
Chair(s)	Part 2: Position Statement and Campaign of International Societies - Young-Tak Kim (CHA University)	
16:10-16:35	<b>Benefits for Asian societies in IPVC 2025 and AI in cervical cancer screening and management</b> Siriwan Tangjitgamol (Vajira Hospital)	
16:35-16:55	<b>Global cervical cancer awareness campaign</b> Hyo Sook Bae (For C Campaign.org)	
16:55-17:05	Discussion	



**Korean Society of Gynecologic Oncology**

# KSGO International Conference 2025

The 40th Annual Meeting of  
Korean Society of Gynecologic Oncology

---

## SCIENTIFIC PROGRAMS DAY 2

JGO Workshop  
Industry Session VII - Chong Kun Dang  
Scientific Session II  
Collaborative Session: TGCS  
Mini-Oral II  
Mini-Oral III  
Collaborative Session: TAGO  
Industry Session IV - GSK  
Industry Session V - Takeda  
Industry Session VI - Roche Diagnostics  
Tumor Board  
Collaborative Session: KGOG  
Young Investigator Session  
Debate Session  
Collaborative Session: KGCR  
Nursing Session (Kor.)





## • April 26 (Saturday)

08:30-09:30	<b>JGO Workshop: Appropriate Use of AI in Writing and Reviewing Scientific Papers</b>	Hall C
Chair(s)	Siriwan Tangjitgamol (Vajira Hospital), Hidemichi Watari (Hokkaido University)	
08:30-08:50	<b>AI-empowered manuscript writing</b> Yusuke Kobayashi (University of Tsukuba)	
08:50-09:10	<b>Case study: AI application</b> Dong Hoon Suh (Seoul National University)	
09:10-09:30	Q&A	

## • April 26 (Saturday)

08:00-08:40	<b>Industry Session VII</b> 	Hall A
Chair(s)	Yong Beom Kim (Seoul National University)	
08:00-08:30	<b>New insight into strategies used to long-acting G-CSF for prevention of neutropenia</b> Jeong-Yeol Park (University of Ulsan)	
08:30-08:40	Floor discussion	

## • April 26 (Saturday)

09:30-11:30	Scientific Session II (Endometrium)	Hall A
Chair(s)	Byoung-Gie Kim (Sungkyunkwan University), Sang Hoon Kwon (Keimyung University)	
09:30-09:50	<b>Role of adjuvant therapy in early-stage endometrial cancer</b> Philipp Harter (Ev. Kliniken Essen-Mitte)	
09:50-09:55	<b>Designated discussion</b> Yung-Taek Ouh (Korea University)	
09:55-10:00	Floor discussion	
10:00-10:20	<b>Innovations in molecular subtyping for precision medicine</b> Tadaaki Nishikawa (The Jikei University)	
10:20-10:25	<b>Designated discussion</b> Angela Cho (Jeju National University)	
10:25-10:30	Floor discussion	
10:30-10:50	<b>Importance of follow-up of patients with uterine corpus cancer from the perspective of cardio-oncology</b> Yoichi Kobayashi (Kyorin University)	
10:50-10:55	<b>Designated discussion</b> Yu-Jin Koo (Yeungnam University)	
10:55-11:00	Floor discussion	
11:00-11:20	<b>Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without Olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA levels, and efficacy in the DUO-E mismatch repair proficient subpopulation</b> Jae-Weon Kim (Seoul National University)	
11:20-11:25	<b>Designated discussion</b> Jin Hwa Hong (Korea University)	
11:25-11:30	Floor discussion	

## • April 26 (Saturday)

09:30-10:30	<b>Collaborative Session: Current Status of Gynecologic Cancer Treatment in Thailand (TGCS)</b>	Hall B
Chair(s)	Perapong Inthasorn (Mahidol University), Rakchai Buhachat (Prince of Songkhla University)	
09:30-09:45	<b>Endometrial cancer</b> Atthapon Jaishuen (Mahidol University)	
09:45-09:50	<b>Designated discussion</b> Seongmin Kim (Korea University)	
09:50-10:05	<b>Ovarian cancer</b> Kamaitorn Tientong (Rajavithi Hospital)	
10:05-10:10	<b>Designated discussion</b> Yoon Hee Lee (Kyungpook National University)	
10:10-10:25	<b>Cervical cancer</b> Panwad Ratanasrithong (National Cancer Institute of Thailand)	
10:25-10:30	<b>Designated discussion</b> Seungho Lee (Gachon University)	

## • April 26 (Saturday)

10:00-10:40	Mini-Oral II	Hall C
Chair(s)	Seob Jeon (Soonchunhyang University), Chul Min Park (Jeju National University)	
10:00-10:04	<b>Intratumor microbiome-derived butyrate facilitates progesterin resistance by inducing ferroptosis in endometrial cancer</b> Xingchen Li (Peking University)	
10:04-10:08	Discussion	
10:08-10:12	<b>Survival outcomes of PCS vs. ICS in advanced ovarian cancer according to institutional criteria during the TRUST trial enrollment period</b> Jae Kyung Bae (National Cancer Center)	
10:12-10:16	Discussion	
10:16-10:20	<b>Histopathologic validation of 2023 FIGO stage IA1–IIIC2 endometrial carcinoma: A retrospective analysis of two tertiary centers in South Korea and Taiwan</b> Myeong-Seon Kim (Chung-Ang University)	
10:20-10:24	Discussion	
10:24-10:28	<b>Updates on prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC, KGOG 3064/KROG 2204)</b> Sangjoon Park (Yonsei University)	
10:28-10:32	Discussion	
10:32-10:36	<b>The Forkhead box protein A1 gene exhibits oncogenic properties in ovarian cancer and can serve as a diagnostic biomarker</b> Eunjung Yang (Soonchunhyang University)	
10:36-10:40	Discussion	


## • April 26 (Saturday)

10:40-11:20	Mini-Oral III	Hall C
Chair(s)	Ki Hyung Kim (Pusan National University), Ju-Won Roh (CHA University)	
10:40-10:44	<b>Evaluation for risk factors against expectant management in cervical intraepithelial neoplasia: A multicenter real-world cohort study</b> Heekyoung Song (The Catholic University of Korea)	
10:44-10:48	Discussion	
10:48-10:52	<b>Survival implications of sarcopenia in epithelial ovarian cancer patients undergoing bowel surgery</b> Jihye Kim (Chung-Ang University)	
10:52-10:56	Discussion	
10:56-11:00	<b>Type-specific risk of high-risk human papillomavirus (HR-HPV) for cervical intraepithelial neoplasia 2 or worse in HR-HPV positive women with mildly abnormal cervical cytology</b> Min-Jeong Kim (CHA University)	
11:00-11:04	Discussion	
11:04-11:08	<b>Effectiveness of HPV vaccination across age groups: The Korean HPV cohort study</b> Sanha Lee (The Catholic University of Korea)	
11:08-11:12	Discussion	
11:12-11:16	<b>The value of the naples prognostic score as a predictor of cancer progression in cervical cancer</b> Seon Mi Lee (Korea University)	
11:16-11:20	Discussion	

## • April 26 (Saturday)


10:30-11:30	<b>Collaborative Session: Current Status of Gynecologic Cancer Treatment in Taiwan (TAGO)</b>	Hall B
Chair(s)	Cheng-Chang Chang (China Medical University Hospital), Kung-Liahng Wang (Mackay Memorial Hospital)	
10:30-10:45	<b>Focusing on the recent progress of the three major gynecological cancers from a clinical perspective in Taiwan</b> Peng-Hui Wang (Taipei Veterans General Hospital)	
10:45-10:50	<b>Designated discussion</b> Won Moo Lee (Hanyang University)	
10:50-11:05	<b>Experience sharing about hyperthermic intraperitoneal chemotherapy for ovarian, fallopian tubal and primary peritoneal cancers in a tertiary referral medical center in Taiwan</b> Jen-Ruei Chen (MacKay Memorial Hospital)	
11:05-11:10	<b>Designated discussion</b> Sanghoon Lee (Korea University)	
11:10-11:25	<b>Fallopian tube organoids: A novel approach for the discovery of early copy number alterations of high-grade serous ovarian cancer</b> Hung-Cheng Lai (Taipei Medical University)	
11:25-11:30	<b>Designated discussion</b> Eunjung Yang (Soonchunhyang University)	

## • April 26 (Saturday)


11:50-12:20	<b>Industry Session IV</b> 	Hall A
Chair(s)	Dae-Yeon Kim (University of Ulsan)	
11:50-12:10	<b>Illuminating advances: Transformative role of dostarlimab in advanced/recurrent endometrial cancer treatment</b> Hee Seung Kim (Seoul National University)	
12:10-12:20	Floor discussion	



## • April 26 (Saturday)

11:50-12:20	<b>Industry Session V</b> 	Hall B
Chair(s)	Jae-Weon Kim (Seoul National University)	
11:50-12:10	<b>Exploring optimal PARP inhibitor treatment in advanced ovarian cancer</b> Bradley Monk (Florida Cancer Specialists and Research Institute)	
12:10-12:20	Floor discussion	

## • April 26 (Saturday)

11:50-12:20	<b>Industry Session VI</b> 	Hall C
Chair(s)	Jae Hong No (Seoul National University)	
11:50-12:10	<b>The new paradigm (CINtec PLUS): Dual stain triage for cervical cancer screening</b> Heekyoung Song (The Catholic University of Korea)	
12:10-12:20	Floor discussion	

## • April 26 (Saturday)

12:50-14:20	<b>Tumor Board: Multinational Tumor Board on Gynecologic Cancer: Exploring Treatment Landscapes</b>	Hall A
Chair(s)	Yoo-Young Lee (Sungkyunkwan University)	
Panel(s)	Siriwan Tangjitgamol (Vajira Hospital) Won Kyung Cho (Sungkyunkwan University) Tricia Dewi Angggraeni (Universitas Indonesia) Hiroyuki Kanao (Cancer Institute Hospital) Jen-Ruei Chen (MacKay Memorial Hospital) Yang Xiang (Peking Union Medical Center Hospital)	

## • April 26 (Saturday)

12:50-14:20	<b>Collaborative Session: KGOG - For the Glory of KGOG and KSGO</b>	Hall B
Chair(s)	Jae Hoon Kim (Yonsei University)	
12:50-13:00	<b>Beginning and past of KGOG: Foundations of progress</b> Yong Man Kim (University of Ulsan)	
13:00-13:10	<b>KGOG Today: Advancing gynecologic oncology</b> Dae-Yeon Kim (University of Ulsan)	
13:10-13:20	<b>Cervical cancer innovations: KGOG-led studies and outcomes</b> Sang Wun Kim (Yonsei University)	
13:20-13:30	<b>Endometrial cancer insights: KGOG-led research contributions</b> Jeong-Yeol Park (University of Ulsan)	
13:30-13:40	<b>Ovarian cancer breakthroughs: Spotlight on KGOG-led studies</b> Chel Hun Choi (Sungkyunkwan University)	
13:40-13:50	<b>Overview of the 400X protocol: Insights from the surgery and DDT committee</b> Eun-Ju Lee (Chung-Ang University)	
13:50-14:00	<b>Collaborating for progress: KGOG's role in NRG studies</b> Min Kyu Kim (Sungkyunkwan University)	
14:00-14:10	<b>Expanding horizons: KGOG's participation in GOG-partners research</b> Jae Yun Song (Korea University)	
14:10-14:20	<b>Global collaboration in gynecologic Oncology: KGOG in ENGOT, JGOG, and EAGOT initiatives</b> Min Chul Choi (University of Ulsan)	

## • April 26 (Saturday)

12:50-14:20	Young Investigator Session	Hall C
Chair(s)	Sunghoon Kim (Yonsei University), Myong Cheol Lim (National Cancer Center)	
12:50-12:57	<b>Clinical application of circulating tumor DNA for tumor profiling and monitoring in high-grade serous ovarian cancer</b> Se Ik Kim (Seoul National University)	
12:57-13:00	Discussion	
13:00-13:07	<b>A multicenter study of laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and Sertoli-Leydig cell tumors: (LARGES): Gynecologic oncology research investigators collaboration study (GORILLA-3005)</b> Jimin Lee (Ajou University)	
13:07-13:10	Discussion	
13:10-13:17	<b>Clinicopathological characters, immunotherapy efficacy and oncological outcomes of gastric-type endocervical adenocarcinoma</b> Ming Du (Peking Union Medical College Hospital)	
13:17-13:20	Discussion	
13:20-13:27	<b>Is it safe to reserve uterus after live-birth following fertility-sparing treatment of endometrial cancer and atypical hyperplasia: A long-term retrospective cohort study</b> Yiqin Wang (Peking University People's Hospital)	
13:27-13:30	Discussion	
13:30-13:37	<b>Cell-free and concentrated ascites reinfusion therapy (CART) shows enhanced efficacy in gynecological cancer patients: A post-marketing surveillance study</b> Nami Tamura (Juntendo University)	
13:37-13:40	Discussion	
13:40-13:47	<b>Early detection of malignancy, and identify key molecules involved in ovarian tumor metastasis using plasma and saliva-derived exosomes in 90 cases</b> Yuichi Shoburu (The University of Tokyo)	
13:47-13:50	Discussion	
13:50-13:57	<b>When pathology diverges: Investigating discrepancies between original and review diagnoses in cervical cancer and precancer</b> Nida Jareemit (Mahidol University)	
13:57-14:00	Discussion	
14:00-14:07	<b>Prevalence and factors associated with discrepancies between original and review pathology examinations in referral cases of premalignant and malignant endometrial lesions</b> Jira-Bhadhra Wongwathanvikroml (Mahidol University)	
14:07-14:10	Discussion	
14:10-14:17	<b>The role of radical mastectomy on breast metastasis from ovarian high grade serous carcinoma origin: A rare case report</b> Gerald Sebastian Davis (Universitas Indonesia)	
14:17-14:20	Discussion	

## • April 26 (Saturday)

14:40-16:10	<b>Debate Session</b>	Hall A
Chair(s)	Jeong-Yeol Park (University of Ulsan)	
<b>Optimal surgical approach for early-stage cervical cancer</b>		
14:40-14:52	<b>Favor minimally invasive surgery</b> Yang Xiang (Peking Union Medical Center Hospital)	
14:52-15:04	<b>Favor open surgery</b> Philipp Harter (Ev. Kliniken Essen-Mitte)	
15:04-15:10	<b>Discussion</b> Seung Hyuk Shim (Konkuk University)	
<b>How to improve survival outcome in locally advanced cervical cancer</b>		
15:10-15:22	<b>Favor addition of neoadjuvant chemotherapy or immune check point inhibitor to CCRT</b> Christina Fotopoulou (Imperial College London)	
15:22-15:34	<b>Favor addition of debulking surgery to CCRT</b> Ju-Won Roh (CHA University)	
15:34-15:40	<b>Discussion</b> Sunmin Park (Korea University)	
<b>Optimal management of recurrent cervical cancer in irradiated pelvis</b>		
15:40-15:52	<b>Favor surgical management including pelvic exenteration</b> Hiroyuki Kanao (Cancer Institute Hospital)	
15:52-16:04	<b>Favor non-surgical management</b> Jen-Ruei Chen (MacKay Memorial Hospital)	
16:04-16:10	<b>Discussion</b> Hee Seung Kim (Seoul National University)	

## • April 26 (Saturday)

14:40-16:10	<b>Collaborative Session: KGCR - Innovations in Gynecological Cancer Translational Research: Current Trends and Future Directions</b>	Hall B
Chair(s)	Yoo-Young Lee (Sungkyunkwan University), Yusuke Kobayashi (University of Tsukuba)	
14:40-15:00	<b>Translational research approaches utilizing PDX and PDO models in gynecologic cancer</b> Jeong-Won Lee (Sungkyunkwan University)	
15:00-15:20	<b>Development of novel personalized medicine for ovarian clear cell carcinoma</b> Shogo Shigeta (Tohoku University)	
15:20-15:40	<b>Therapy of drug resistant ovarian cancer</b> Jaeho Kim (Pusan National University)	
15:40-16:00	<b>New findings of basic research on PARP and functional analysis of SLFN11 related to therapeutic effect of PARP inhibitors</b> Junko Murai (Ehime University)	
16:00-16:10	Discussion	

## • April 26 (Saturday)

14:40-16:00	<b>Nursing Session</b> (Kor.)	Hall C
Chair(s)	Young Soo Chu (Korea University Anam Hospital), Woong Ju (Ewha Womans University)	
14:40-14:55	<b>The latest treatment for gynecologic cancer: Immuno-oncologic drug</b> Nam Kyeong Kim (Korea University)	
14:55-15:00	Floor discussion	
15:00-15:15	<b>Management of immuno-oncologic drug side effects</b> Joo Hyun Kim (Samsung Medical Center)	
15:15-15:20	Floor discussion	
15:20-15:35	<b>Radiation therapy and side effect management in gynecologic cancer patients</b> Hye Sung Moon (Ewha Womans University Mokdong Hospital)	
15:35-15:40	Floor discussion	
15:40-15:55	<b>Pathologic and genetic testing in gynecologic cancer patients</b> Soo Hyun Oh (Gachon University)	
15:55-16:00	Floor discussion	





**Korean Society of Gynecologic Oncology**

# KSGO International Conference 2025

The 40th Annual Meeting of  
Korean Society of Gynecologic Oncology

---

**E-POSTER EXHIBITION**

**SURGICAL FILM  
SCREENING**



## E-POSTER EXHIBITION

08:30-16:10		Hall D
PE-01	NIR-II fluorescence imaging based on Trop-2-targeting peptide guides precise resection of abdominal metastases from ovarian cancer Chengxi LI (Xiamen University)	
PE-02	Development of a blood cell analysis-based AI model for early detection of ovarian cancer (Withdrawal) Se Ik Kim (Seoul National University Hospital)	
PE-03	Prevalence of homologous recombination deficiency in Korean patients with epithelial ovarian cancer Junhwan Kim (National Cancer Center)	
PE-04	Clinical and molecular characteristics of patients with high-grade serous ovarian cancer recurring on PARP inhibitors Hyun Park (CHA Bundang Medical Center)	
PE-05	Mortality rate changes related to trends in the use of neoadjuvant chemotherapy in ovarian cancer in South Korea: an analysis using national cancer registry data Jun-Hyeong Seo (Samsung Medical Center)	
PE-06	Screening of germline variants using tumor multigene panel in gynecological cancer (Withdrawal) Kidong Kim (Seoul National University Bundang Hospital)	
PE-07	Drug repurposing of biguanides: exploring the anti-cancer effects of phenformin and metformin in epithelial ovarian cancer Jihye Kim (Chung-Ang University Hospital)	
PE-08	Genomic analysis of PARP inhibitor response in high-grade serous ovarian cancer: Insights from whole genome sequencing (Withdrawal) Ok-Ju Kang (Ulsan University Hospital)	
PE-09	The gene expression signature of niraparib treatment in HRP ovarian cancer cells Zhong Zheng (Fudan University Shanghai Cancer Center)	
PE-10	The role of Gonadotropin-releasing hormone 2 in epithelial ovarian cancer Eun-Ju Lee (Chung-Ang University)	
PE-11	Comprehensive analysis of germline variants and clonal hematopoiesis in Ovarian Cancer patients using whole exome sequencing Hye-Lim Cho (Incheon National University)	
PE-12	cfDNA fragmentation signatures and a novel framework for epigenome-dependent analysis: Potential application in HRD and signature 3 (Withdrawal) Yoo-Na Kim (Harvard Medical School)	
PE-13	Development and validation of a blood-based high-Specificity PCR algorithm for diagnosis of ovarian cancer (Withdrawal) Se Ik Kim (Seoul National University Hospital)	
PE-14	Development of a next generation sequencing cancer panel-based homologous recombination deficiency test in epithelial ovarian cancer (Withdrawal) Se Ik Kim (Seoul National University Hospital)	
PE-15	Clinical and genetic predictive factors of PARP inhibitor efficacy in advanced or recurrent ovarian cancer In Sun Hwang (Seoul ST. Mary's Hospital)	
PE-16	Preoperative MRI metrics as predictor of progression-free survival in epithelial ovarian cancer Heekyoung Song (Incheon ST. Mary's Hospital)	
PE-17	Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer Maiko Yamaguchi (National Cancer Center Research Institute)	

PE-19	Postoperative systemic immune-inflammatory index (SII) as a prognostic factor in Epithelial ovarian cancer Young Eun Chung (Samsung Medical Center)
PE-20	A retrospective study of 11 cases from a single institution: malignant transformation arising from mature cystic teratoma Minseong Choi (Inje University Haeundae Paik Hospital)
PE-21	Optimizing HIPEC protocols: Preventive approaches for cisplatin-Induced AKI in ovarian cancer Jimin Lee (Ajou University Medical Center)
PE-22	The association between location of BRCA mutation and efficacy of PARP inhibitor as a frontline maintenance therapy in advanced epithelial ovarian cancer Ji Hyun Kim (National Cancer Center)
PE-23	Comparative efficacy of Olaparib and niraparib in maintenance therapy for brca-mutated epithelial ovarian cancer: A real-world survival analysis Yae-Sol Kim (Asan Medical Center)
PE-24	Treatment results using PARP inhibitors for advanced ovarian cancer - From our hospital data - Miseon Nakazawa (NTT Medical Center Sapporo)
PE-25	ESRP1-Mediated alternative splicing in ovarian cancer: Insights from RNA splicing analysis and evolutionary patterns in tumor cells Xihan Liu (Qilu Hospital Shandong University)
PE-26	Clinical and survival outcomes of controlled suction technique with minimal spillage in the patients presented with huge ovarian cyst Nam Kyeong Kim (Korea University Ansan Hospital)
PE-27	Maintenance of PARP inhibitor rechallenge plus Bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R) Hyun-Woong Cho (Korea University Guro Hospital)
PE-28	Survival outcomes and prognostic factors in advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer Mohamad Nurfadli Senin (Ministry of Health)
PE-29	Study of fatty acids promoting lymphovascular space invasion in endometrial cancer through ITGB3-ICAM1-TRPV4 mediating mechanical crosstalk between cancer cells and endothelial cells Jingyuan Wang (Peking University People's Hospital)
PE-30	Usefulness of droplet digital polymerase chain reaction (ddPCR) assay for POLE mutation in the molecular endometrial cancer staging system and comparison of survival prognosis with the 2009 FIGO Stage Sung Jong Lee (Seoul ST. Mary's Hospital)
PE-31	The neutrophil-albumin index as a discriminative tool for distinguishing uterine leiomyosarcoma from uterine leiomyoma Hyung Joon Yoon (Pusan National University Hospital)
PE-32	Endometrial cancer detected unusually after an ankle fracture secondary to severe anemia in an obese woman with heavy menstrual bleeding: A case report Hyung Joon Yoon (Pusan National University Hospital)
PE-33	Evaluating offspring growth and behavioral development after maternal fertility-sparing treatment of early endometrial cancer or atypical endometrium hyperplasia: A multicentre observational study Yifan Feng (Peking University People's Hospital)
PE-34	Usefulness of blood NGS tests in endometrial cancer Eunhye Cho (Inje University Busan Paik Hospital)
PE-35	Metabolic syndrome combined with insulin resistance showed great predictive value in evaluating recurrence in patients with atypical endometrial hyperplasia and early endometrial cancer Xingchen Li (Peking University People's Hospital)

## E-POSTER EXHIBITION

PE-36	Association between dietary inflammatory index and risk of endometrial cancer in the prostate, lung, colorectal, and ovarian cancer screening trial Kun Song (Qilu Hospital, Shandong University)
PE-37	Effect of smoking status on endometrial cancer risk by menopausal status: A nationwide cohort study Sung Jong Lee (Seoul ST. Mary's Hospital)
PE-38	High glucose promotes metastasis and stemness of endometrial cancer by regulating IGF2BP1 -Mediated m6A methylation of CITED2 mRNA Chengcheng Li (Peking University People's Hospital)
PE-39	SORBS3- $\beta$ promotes ubiquitination and degradation of $\beta$ -catenin to suppress lymph node metastasis in cervical cancer Huating Sun (The First Affiliated Hospital of Soochow University)
PE-40	Molecular characterization of advanced endometrial cancer Mi-Kyung Kim (Ewha Womans University Medical Center)
PE-41	The mechanism study of lipid metabolism disorder to promote lymphovascular space invasion in endometrial cancer by regulating PI3K/Akt axis mediated by ITGB3 Jingyuan Wang (Peking University People's Hospital)
PE-42	Different maintenance treatment regimens for recurrence after fertility sparing treatment in patients with endometrial cancer and atypical endometrial hyperplasia Zerui Xiao (Peking University People's Hospital)
PE-43	Precision molecular profiling of endometrial cancer: Evaluating ddPCR for POLE mutation detection Yung-Taek Ouh (Korea University Ansan Hospital)
PE-44	Prognostic significance of Systemic immune-inflammation index (SII) in endometrial cancer: Highlighting the predictive value of post-chemotherapy SII for survival outcomes Seongyun Lim (Samsung Medical Center)
PE-45	Association between Estrogen receptor/Progesterone receptor Status and Risk Factors in Postmenopausal Women with Endometrioid Type Endometrial Cancer Yongil Ji (Inje University Haeundae Paik Hospital)
PE-46	Predictive value of primary tumor SUVmax on 18F-fluro-2-deoxy-D-glucose positron emission tomography and computed tomography in patients undergoing fertility-sparing treatment for early endometrial cancer Eun Bi Jang (Konkuk University)
PE-47	Endometrial carcinosarcoma presenting as nonpuerperal uterine inversion in a 44-year-old virgin: a case report Nam Kyeong Kim (Korea University Ansan Hospital)
PE-48	Bariatric surgery: A promising adjunct to fertility-sparing treatment in obese endometrial cancer patients Jin Lai (Peking University People's Hospital)
PE-49	FOXA2-mediated recovery of PR expression: A molecular approach against PR-negative endometrial cancer Jie Liu (Peking University)
PE-50	Immunotherapy and progestin therapy lead to different pathological responses and immune microenvironment as fertility-sparing strategies in MMRd endometrial cancer Yiqin Wang (Peking University People's Hospital)
PE-51	Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without Olaparib for endometrial cancer: Mismatch repair deficient and/or microsatellite instability-high subpopulation efficacy analyses from the DUO-E trial Jae-Weon Kim (Seoul National University Hospital)
PE-52	Preclinical evaluation for the efficacy of JPI-547, a dual inhibitor of PARP 1/2 and tankyrase 1/2, in endometrial cancer cell lines Hyerim Eum (Asan Medical Center)

## E-POSTER EXHIBITION

PE-53	Comparison on surgical outcomes by open, laparoscopy and robotic surgery in obese women with endometrial cancer Thitisak Vanichpakorn (Prince of Songkla University)
PE-54	Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities: Challenge or opportunity? Jianliu Wang (Peking University People's Hospital)
PE-55	Efficient and minimally invasive: Robotic SP®-Assisted VNOTES for endometrial cancer management Gyul Jung (Seoul ST. Mary's Hospital)
PE-56	Clinical efficacy of molecular classification for endometrial cancer: preliminary results from a single-center study Seung Ho Kim (Hallym University Dongtan Sacred Heart Hospital)
PE-57	Corded and hyalinized endometrioid endometrial carcinoma: A rare case treated with robot-assisted surgery Su Jeong Lee (Uijeongbu ST. Mary's Hospital)
PE-58	Examination of the functions and mechanism of KCP in mediating paclitaxel resistance in cervical squamous carcinoma cells Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-59	ZBTB5 enhances the resistance of cervical cancer to paclitaxel by regulating BCL6 Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-60	Establishment of a risk prediction model for predicting cervical lesions in HR-HPV positive women based on host six-gene methylation Bin Li (Shaanxi Provincial People)
PE-61	Persistent inflammation and abnormal finding in physical exam: Surgical decisions in persistent high-risk HPV infections without HSIL results Hyun Jin Choi (Chung-Ang University Hospital)
PE-62	The significance of HPV 18 in neuroendocrine carcinoma of the cervix (Withdrawal) Se Ik Kim (Seoul National University Hospital)
PE-63	Association between underlying comorbidities and the risk of cervical cancer: A retrospective cohort study in the South Korea Yongwook Kim (Incheon ST. Mary's Hospital)
PE-64	Hematopoietic stem cell-containing autologous blood transfusion for bone marrow protection in patients with cervical cancer Na Zhang (Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital)
PE-65	A comparative study of cervicovaginal microbiome in women with or without human papillomavirus infection Kavita Khoiwal (AIIMS Rishikesh)
PE-66	Excessive carbohydrate intake associated with higher risk of cervical cancer in Korea : Korean national health and nutrition examination survey 2016-2021 Seon Mi Lee (Korea University Anam Hospital)
PE-67	The impact of physical activity on mortality among women with cervical cancer Young Eun Chung (Samsung Medical Center)
PE-68	Cervical HPV prevalence and analysis of human leukocyte antigen among women with hematologic malignancies Min Jin Jeong (Eunpyeong St. Mary's Hospital)
PE-69	Kielin chordin protein as a biomarker predicting chemo-resistance in cervical cancer to paclitaxel Chen Ji (Beijing Obstetrics and Gynecology Hospital)
PE-70	Prognostic analysis of patients with locally advanced cervical cancer undergoing radical hysterectomy Yong Zhao (Qilu Hospital of Shandong University)

## E-POSTER EXHIBITION

PE-71	Assessment of reproductive outcomes of patients with early-stage (IA1-IB1) cervical cancer after repeated conization versus single conization Beihua Kong (Qilu Hospital of Shandong University)
PE-72	Risk factors for high-grade squamous intraepithelial lesion recurrence after the two-layer loop electrosurgical excision procedure in patients with positive endocervical, exocervical, and deep margins In Sun Hwang (Seoul ST. Mary's Hospital)
PE-73	Mixed neuroendocrine tumor of the cervix has a poorer prognosis than pure neuroendocrine tumor (NECXT) (Withdrawal) Kidong Kim (Seoul National University Bundang Hospital)
PE-74	A case of cervical carcinoma with perforation of pyometra of the uterus Kengo Hiranuma (Juntendo University)
PE-75	Results of treatment for FIGO stage I-II vulvar squamous cell carcinoma at Viet Nam National cancer Hospital Anh Nguyen (Vietnam National Cancer Hospital)
PE-76	Real-world efficacy and survival of PD-1/PD-L1 monoclonal antibody-based immunotherapy in cervical cancer Xinran Li (Peking Union Medical College Hospital)
PE-77	Sensitivity prediction to uterine artery interventional chemoembolization in locally advanced cervical cancer with MRI-based radiomics Bin Li (Shaanxi Provincial People's Hospital)
PE-78	Assessment of preoperative ultrasound for predicting the feasibility of minimally invasive surgery in early-stage cervical cancer: A pilot study Kyung Jin Eoh (Yongin Severance Hospital)
PE-79	Effect of using McCartney tube to reduce tumor spillage during minimally invasive radical hysterectomy for cervical cancer Seongmin Kim (Korea University Anam Hospital)
PE-80	Comparative analysis of laparoscopic, robotic-assisted, and abdominal radical hysterectomy for early-stage cervical cancer: A 22-year retrospective study Changmin Shin (Keimyung University Dongsan Medical Center)
PE-81	Silk-based nanoparticle for enhanced paclitaxel delivery and targeted anticancer therapy in cervical cancer Jung Hwan Ahn (Wonju Severance Christian Hospital)
PE-82	Normalization of posttreatment squamous cell carcinoma antigen (SCC Ag) as a prognostic marker in patients with advanced cervical cancer treated with first-line bevacizumab–paclitaxel–cisplatin therapy Haa-Na Song (Gyeongsang National University Hospital)
PE-83	Construction and validation of a prognostic prediction model for aggressive histotype endometrial carcinoma Beihua Kong (Qilu Hospital of Shandong University)
PE-84	Marker discovery of serum circulating metabolites distinguishing CIN from normal for cervical cancer prevention Eunjung Yang (Soonchunhyang University Hospital Cheonan)
PE-85	Prognostic impact of positive margins after LEEP in patients with cervical intraepithelial neoplasia Changmin Shin (Keimyung University Dongsan Medical Center)
PE-86	Detection of microbial infections and antibiotic resistance within 90 minutes in urine and blood samples of symptomatic patients with paper-based electrochemical DNA biosensor Kavita Khoiwal (AIIMS Rishikesh)
PE-87	Indocyanine green vs. methylene blue: A comparative study on sentinel lymph node detection in early-stage endometrial cancer Rahima Nazarova (National Oncology Center)



## E-POSTER EXHIBITION

PE-88	Changes of disease spectrum of malignant tumor of female reproductive system in Beijing Obstetrics and Gynecology Hospital in recent 60 years Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-89	Treatment of radiation-induced vaginal stenosis using the martius-symmonds flap Ilnur Musin (Bashkir State Medical University)
PE-90	An international prospective comparative study on articulating laparoscopic instruments in benign adnexal gynecologic surgery Young Eun Chung (Samsung Medical Center)
PE-91	Genomic and transcriptomic profiling of Lynch Syndrome patients with unaffected carrier status, premalignant lesion, and endometrial carcinoma Yoo-Na Kim (Severance Hospital)
PE-92	Feasibility exploration of constructing a patient derived tumor tissue xenograft (PDX) model for malignant tumors of the female reproductive system in mice Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-93	A unique case of recurrent LCH involving the bilateral vulva Na Zhang (Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital)
PE-94	Impact of gut microbiota on immune checkpoint inhibitor efficacy in gynaecological cancers Hyun Jin Choi (Chung-Ang University Hospital)
PE-95	Radiofrequency ablation Amartuvshin Tumenjargel (Mongolia-Japan Teaching Hospital)
PE-96	Primary peritoneal carcinoma mimicking advanced ovarian cancer Kyongjin Kim (Presbyterian Medical Center)
PE-97	Hysterectomy for benign gynecologic disease: A comparative study of articulating laparoscopic instruments and robot-assisted surgery in Korea and Taiwan Jun-Hyeong Seo (Samsung Medical Center)
PE-98	Feasibility of laparoscopic hysterectomy using an articulating laparoscopic instrument: A prospective observational study Jun-Hyeong Seo (Samsung Medical Center)
PE-99	Comparison of artisential and conventional laparoscopic instruments in hysterectomy for gynecologic cancers: A hybrid observational study on surgical outcomes, pain control, and oncologic safety Seongyun Lim (Samsung Medical Center)
PE-100	Application of the whole-course management model in patients with endometrial cancer or atypical hyperplasia undergoing fertility preservation Yuan Yuan Liu (Peking University People's Hospital)
PE-101	Risk factors associated with residual lesions in subsequent hysterectomy after loop electrosurgical excision procedure Minseong Choi (Inje University Haeundae Paik Hospital)
PE-102	The impact of ME1 expression on tumor progression and immunotherapy in ovarian cancer: a comprehensive analysis Jiahui Wei (Beijing Obstetrics and Gynecology Hospital)
PE-103	A comprehensive mRNA-lncRNA signature predicts lymph node metastasis in cervical cancer patients Jiahui Wei (Beijing Obstetrics and Gynecology Hospital)
PE-104	Unexpected premalignant and malignant lesion of endometrium and ovary in fertility workup Suresh Kayastha (Kathmandu Cancer Center)



## E-POSTER EXHIBITION

PE-105	Histology type profile of endometrial abnormalities: A five-year prevalence study Insi Hidayatul Husna (Andalas University)
PE-106	Analysis of histology type from uterine cervix biopsy in Padang: A five-year retrospective study Wendy Armi (Faculty of Medicine, Andalas University)
PE-107	Pathological examination overview of uterine tumors indicative of uterine cancer : A five-year retrospective study M. Fikri Ridha (Andalas University)
PE-108	Histology analysis of ovarian tumors: A five-year retrospective study in an Indonesian Regional Hospital Kelsy Qoridisa (Andalas University)
PE-109	High P63 expression associated with better survival outcome in FIGO stage IIC1p cervical cancer Jiao Wang (Beijing Obstetrics and Gynecology Hospital)
PE-110	CASE report: Challenges in management of malignant mixed mullerian tumour Kay Thi (University of Medicine -2, Yangon)
PE-111	Intraoperative mesenteric lymphatic mapping to prevent chylous leakage: A case report Chowon Park (CHA University)

## SURGICAL FILM SCREENING

08:30-16:10		Hall D
SF-02	A comprehensive guide to vNOTES pelvic lymphadenectomy in early-stage endometrial cancer Sujin Lee (Seoul ST. Mary's Hospital)	
SF-03	How to use the indocyanine green after sentinel lymph node biopsy during staging surgery Won Moo Lee (Hanyang University)	
SF-04	Robotic primary staging surgery in stage IIIA ovarian cancer Seon-Mi Lee (Korea University Anam Hospital)	
SF-05	Early experience of DV5 system for endometrial cancer using lower pelvic port placement Seongmin Kim (Korea University Anam Hospital)	



**Korean Society of Gynecologic Oncology**

# **KSGO**

# **International Conference 2025**

The 40th Annual Meeting of  
Korean Society of Gynecologic Oncology

---

**CONGRESS INFORMATION**

**FLOOR PLAN**

**ACKNOWLEDGEMENTS**

## CONFERENCE INFORMATION

### Registration

Registration is required to participate in the KSGO International Conference 2025, the 40th Annual Meeting of the Korean Society of Gynecologic Oncology.

Pre-registered participants who did not complete payment in advance must pay the on-site registration fee.

>> **Location** Lobby, ST Center (1F)

>> **Operating Hours** April 25 (Fri) 08:00-18:00 | April 26 (Sat) 07:30-16:30

### Name Badge Policy

All congress activities including educational sessions, meal functions, and the exhibit hall are exclusively reserved for registered attendees. All participants must wear their personal name badges at all times during the congress to access the venue.

Your name badge includes your receipt, certificate of attendance, and coupons.

\* If you need to update or correct your badge, please visit the registration desk.

### Preview Room

All speakers are required to visit the preview room and check their presentation files at least 30 minutes before their session.

>> **Location** Preview Room, ST Center (B1)

>> **Operating Hours** April 25 (Fri) 07:30-18:00 | April 26 (Sat) 07:00-16:30

### Presenter Notice

- Presentations in English (except select sessions)
- Adhere to your presentation time for a smooth session flow.
- If your file includes video or audio, inform the staff in advance.
- Use standard fonts and make sure your file is final to avoid font issues.

### Booth Exhibition

Visit the exhibition booths to receive the latest updates on products and innovations.

>> **Location** Lobby & Exhibition Hall, ST Center (B1)

>> **Opening Hours** April 25 (Fri) 08:00-18:00 | April 26 (Sat) 07:30-16:30

### VIP Room / Speakers Room

To ensure the convenience and comfort of our esteemed speakers and VIP guests, a dedicated VIP Room / Speakers Room will be available throughout the conference.

>> **Location** ST Center (B1)

>> **Operating Hours** April 25 (Fri) 08:00-18:00 | April 26 (Sat) 07:30-16:30

### Prayer Room

For the convenience of participants who require a private space for prayer, a Prayer Room will be available throughout the duration of the conference.

>> **Location** Meeting Room 5, ST Center (B1)

>> **Operating Hours** April 25 (Fri) 08:00-18:00 | April 26 (Sat) 07:30-16:30

# CONFERENCE INFORMATION

## E-posters & Surgical Films

All E-posters and surgical films will be displayed throughout the conference period.

We encourage you to take time during coffee and lunch breaks to view the presentations.

>> Location Hall D, ST Center (B1)

>> Opening Hours April 25 (Fri) 08:00-18:00 | April 26 (Sat) 07:30-16:30

## E-poster Presentation

During the E-poster Session, presentations will be given for pre-selected posters.

>> Location Hall D, ST Center (B1)

>> Date & Time April 25 (Fri), 13:40-14:30

### Presenter Notice

- Presenters are kindly asked to arrive at least 10 minutes before the session and be ready near their posters.

## Special Events

Recharge during the conference and enjoy a variety of special events prepared just for you.

### Photo Booth Event

Strike a pose and snap a photo to remember your time at the conference.

### Calligraphy Event

Get your name or a special phrase written by a professional calligrapher.

### Caricature Event

Meet your animated self captured as a charming caricature!

## Shuttle Bus Schedule

Date	Route	Interval	Departure Times	Break Time	Last Bus
Apr 24 (Thu)	Novotel → INTUITIVE Surgical Korea	-	09:00	-	-
Apr 25 (Fri)	Novotel → ST Center	1 hour	08:00, 09:00, 10:00, 11:00, 14:00	11:30-13:00	14:00
	ST Center → Novotel	1 hour	08:30, 09:30, 10:30, 13:30, 14:30, 15:30, 16:30, 17:30	11:30-13:00	17:30
Apr 26 (Sat)	Novotel → ST Center	1 hour	07:00, 08:00, 09:00, 10:00, 11:00, 14:00	11:30-13:00	14:00
	ST Center → Novotel	1 hour	07:30, 08:30, 09:30, 10:30, 13:30, 14:30, 15:30, 17:00	11:30-13:00	17:00

## CONFERENCE INFORMATION

### Giveaway Event

#### Welcome Gift Event

All registered participants will receive a surgical cap as a welcome gift.



Surgical Cap (One per participant)

#### Early-Bird Event

Gifts will be given to the earliest attendees of the meeting. (Up to 50 participants per day).



Red Wine (First 100 participants)

#### Booth Stamp Event

Collect stamps from all booths & get a special gift. Please visit the Prize Pickup Desk in the 1F Lobby to collect your gift.

#### ☒ How to participate

Step 1 Visit all the booths and collect stamps.



Step 2 Collect your gift at the Prize Pickup Desk.



Stanley Tumbler (First 400 participants)

#### >> Location

Lobby, ST Center (1F)

#### >> Opening Hours

April 25 (Fri) 08:00-18:00 | April 26 (Sat) 07:30-16:30

## CONFERENCE INFORMATION

### Lucky Draw

Collect all the stamps and have a chance to win a drawing for premium gifts.

The drawing will be held at the Closing Ceremony (April 26, 16:10-16:40, Hall A).

#### ☑ How to participate

Step 1 Visit all the booths and collect stamps.



Step 2 Present your stamp sheet to the staff and participate in the draw.



Galaxy Tab S10  
(1EA)



iPad Air  
(1EA)



LG Robo-King AI  
(2EA)



Balmuda Toaster  
(3EA)



Nespresso Vertuo  
(3EA)



Logitech Wireless Mouse  
(3EA)



Shinsegae Gift Card  
(5EA)

### Gala Dinner

At KSGO 2025, we have prepared a special dinner event to enhance the friendship and camaraderie among all attendees.

An exciting performance and delicious food will be waiting for you. We sincerely look forward to sharing this precious moment with you.

>> Location

CHAMPAGNE Hall, 2F, Novotel Ambassador Seoul Gangnam

>> Date & Time

April 25 (Fri), 18:30-20:00



## CONFERENCE INFORMATION

### Journal

KSGO 2025 accepted oral and featured poster abstracts will be published in a supplement to JGO, the Journal of Gynecologic Oncology.

### Recognition, Acknowledgements & Industry Support

In accordance with compliance regulations, industry supporting the congress will be acknowledged separately from the scientific program. Industry information will appear at the book.

### Wi-Fi

Exclusive Wi-Fi is available for conference attendees. Please note that the Wi-Fi capacity is limited and is only available for email and web browsing activities.

 ID: KOFST-2 PW: 12345678

### Safety & Security

#### Copyright Notice

Materials distributed during the conference are protected by copyright and may not be reproduced or shared without prior permission.

#### Photography & Media

Photographs will be taken during the conference for promotional purposes. If you do not wish to be photographed, please inform the photographer or a staff member.

#### Insurance Responsibility

The organizers are not responsible for personal accidents or the loss or damage of belongings. Please ensure your insurance coverage is valid during your stay.

#### Lost & Found

Lost items can be reported or inquired about at the registration desk.

## CONFERENCE INFORMATION


### Slido Q&A Information

To facilitate real-time Q&A during the conference, we will be using **Slido.com**.


If you have any questions or comments during the presentations, please feel free to submit them through Slido.

#### How to participate

1. Go to [Slido.com](https://slido.com) in your web browser
2. Scan the QR code displayed on the hall screen to join the session
3. Type your question and submit!

\* You can also upvote other participants' questions by clicking the  icon - the most popular questions will be answered first.  
We encourage your active participation!

### Participant mode



## 대한의사협회 연수평점 for Koreans

### KSGO 2025 평점

>> 4월 25일(금): 6평점

>> 4월 26일(토): 6평점

### 평점인정기준

1. 수강 시작과 종료를 확인할 수 있도록 2회의 출결 확인(바코드 확인) 의무를 시행합니다.
2. 학회 입장과 퇴장 시간을 모두 바코드 시스템을 통해 확인 받으셔야 하며, 실 참석 시간(점심시간 및 쉬는시간 제외)에 따라 다른 평점이 부여됨을 숙지하여 주시기 바랍니다.

1일 체류 시간당 제공 평점			
체류 시간			평점 인정
1시간 이상 - 2시간 미만			1평점
2시간 이상 - 3시간 미만			2평점
3시간 이상 - 4시간 미만			3평점
4시간 이상 - 5시간 미만			4평점
5시간 이상 - 6시간 미만			5평점
6시간 이상			6평점


평점 인정 기준			
구분	입장 시 바코드 인식 확인	퇴장 시 바코드 인식 확인	평점
Case 1	O	X	불인정
Case 2	X	O	불인정
Case 3	X	X	불인정
Case 4	O	O	인정

### 연수교육 이수내역 확인방법

1. 당일 참석하여 2회의 출결 확인(바코드 확인)
2. 연수교육기관은 행사종료 후 28일 이내에 교육 이수자를 의협에 보고
3. 해당교육 이수자 KMA 교육센터(<http://edu.kma.org>)로그인 (ID 및 PW는 대한의사협회 홈페이지와 동일)
4. [마이페이지] → [연수교육 이수내역 확인]란에서 확인

## FLOOR PLAN

1F



## FLOOR PLAN

B1F



## BOOTH EXHIBITION LIST

Grade	Location	Company Name
Diamond	D1	Boryung
	D2	MSD
Platinum	P1	GSK Korea
	P2	HK inno.N
Gold	G1	Roche Diagnostics
	G2	Chong Kun Dang
	G3	Takeda Pharmaceuticals Korea
Silver	S1	Seegene
	S2	NTL Healthcare
	S3	
Bronze	B1	LIVSMED
	B2	Hanmi Science
	B3	dalimbiotech
	B4	Intuitive Surgical
	B5	Johnson & Johnson MedTech
	B6	AstraZeneca Korea
	B7	Becton, Dickinson and Company Korea
	B8	Hanmi Pharmaceutical
	B9	Samyang Holdings
	B10	Applied Medical Korea
Exhibition	E1	Jung Ahn International
	E2	Shin Poong Pharm
	E3	AbbVie
	E4	Verto Korea
	E5	MEDITECH INFRAMED
	E6	Kyongbo Pharm

## ACKNOWLEDGEMENTS

Diamond

BORYUNG



Platinum

GSK

inno.N

## ACKNOWLEDGEMENTS

### Gold



**Chong Kun Dang**  
Pharm.  
Seoul, Korea



### Silver



### Bronze

**LIV'SMED**

**Hanmi Hanmi Science**

**AstraZeneca**

**dalim** (주)다림바이오텍

**INTUITIVE**



**SAMYANG**

Global · R&D Leader  
**Hanmi Hanmi Pharmaceutical**

**Johnson & Johnson**  
MedTech







Korean Society of  
Gynecologic Oncology

# 2025년 대한부인종양학회 제19차 젊은의사 워크숍 & 제8차 분과전문의 연수강좌

일자 2025. 8. 9.(토)

장소 세종대학교 대양AI홀



대한부인종양학회  
Korean Society of Gynecologic Oncology

# 2025년 대한부인종양학회 제30차 추계학술대회

2025.10. 17. (금) - 18. (토)  
호텔인터불고 대구



[www.sgo.or.kr](http://www.sgo.or.kr)




대한부인종양학회  
Korean Society of Gynecologic Oncology

# 2026년 대한부인종양학회 동계학술대회

일자: 2026년 1월 10일 (토)  
장소: 추후 공지

Korean Society of  
Gynecologic Oncology



대한부인종양학회  
Korean Society of Gynecologic Oncology



Korean Society of Gynecologic Oncology

# KSGO International Conference 2026

The 41st Annual Meeting of  
Korean Society of Gynecologic Oncology

---

April **3** (Fri)–**4** (Sat), 2026  
COEX MAGOK, Seoul, Korea

“Next-Gen Gynecologic Oncology:  
Refining Technology, Elevating Care”



# ALL IN JEMPERLI

for your **ALL** advanced/recurrent  
EC patients

젬퍼리는 RUBY 연구를 통해 진행성 또는 재발성 자궁내막암에서 CP 병용요법으로 **유일하게** 유의한 **OS** 개선 효과를 입증한 면역항암제입니다.<sup>2</sup>

- ① 모든 새로 진단된 진행성 또는 재발성 자궁내막암이 있는 성인 환자에게 **1차 치료제(병용요법)**로 허가 받았습니다.<sup>1</sup>
- ② 국내 dMMR/MSI-H 진행성 또는 재발성 자궁내막암 **2차 이상 치료(단독요법)** 최초로 **허가 및 급여** 적용된 면역항암제입니다.<sup>1,3-5</sup>

진행성(stage III, IV) 또는 재발성 자궁내막암 환자를 대상으로 한 **RUBY 연구**에서 확인한 **젬퍼리의 효과**<sup>1,2</sup>

모든 자궁내막암 환자군 (Jemperli+CP군 vs Placebo+CP군)

Median OS	44.6 vs 28.2 mon (HR, 0.69; 95% CI, 0.54-0.89; stratified log-rank P=0.0020)	16.4mon ↑	사망 위험 감소 31% ↓
Median PFS	11.8 vs 7.9 mon (HR, 0.64; 95% CI, 0.51-0.80; P<0.0001)		

dMMR/MSI-H 자궁내막암 환자군 (Jemperli+CP군 vs Placebo+CP군)

Median OS	NR vs 31.4 mon (HR, 0.32; 95% CI, 0.17-0.63; NA)		사망 위험 감소 68% ↓
Median PFS	NR vs 7.7 mon (HR, 0.28; 95% CI, 0.16-0.50; P<0.0001)		

EC, endometrial cancer; dMMR, mismatch repair deficient; MSI-H, microsatellite instability-high; CP, carboplatin-paclitaxel; OS, overall survival; PFS, progression free survival; HR, hazard ratio; CI, confidence interval; NR, not reached.

**RUBY study design<sup>2</sup>:** A total of 494 patients with primary advanced stage III or IV or first recurrent endometrial cancer were included in this phase 3, global, double-blind, randomized, placebo-controlled trial. Patients were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years. The primary end points were progression-free survival(PFS) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors(RECIST), version 1.1, and overall survival(OS).

**Reference:** 1. 식품의약품안전처, 젬퍼리주 의약품상세정보. 2. Powell MA, et al. Ann Oncol. 2024;S0923-7534(24)00721-X. 3. 보건복지부 고시 제2023-220호. 시행일: 2023년 12월 1일. 4. 건강보험심사평가원. 암환자에게 처방, 투약 하는 약제에 대한 요양급여의 적용기준 및 방법에 관한 세부사항. 개정년월일: 2022년 9월. 5. 건강보험심사평가원. 요양급여의 적용기준 및 방법에 관한 세부사항. 2024년 5월.

**Safety Information<sup>1</sup>** 사용상의주의사항 1. 다음 환자에는 신중히 투여할 것. 이 약 및 그 구성 성분에 과민증인 환자 2. 이상사례 1) 임상시험에서 보고된 약물이상반응 GARNET 임상에서 재발성 또는 진행성 자궁내막암 또는 기타 고형 종양이 있는 605명의 환자를 대상으로 단독요법으로서 이 약의 안전성을 평가하였다. 환자들은 4주기 동안 매 3주마다 이 약 500mg 용량을 투여받고 나서 이후 매 6주마다 1000mg을 투여받았다. RUBY 임상에서 새로 진단된 진행성 또는 재발성 자궁내막암 환자 241명을 대상으로 화학요법과의 병용요법으로서 이 약의 안전성을 평가하였다. 환자들은 6주기 동안 매 3주마다 이 약 500mg 용량을 투여받고 나서 이후 매 6주마다 1000mg을 투여받았다. GARNET 임상에서 이 약을 단독요법으로 투여한 환자와 RUBY 임상에서 화학요법과 병용하여 이 약을 투여받은 환자에서 관찰된 이상반응을 열거하였다. 다양한 유형의 항암 요법과 병용하여 이 약을 투여받은 고형암 환자를 대상으로 실시한 다른 임상시험에서 확인된 추가적인 이상반응 또한 포함되어 있다. 이 약 또는 병용요법 구성 성분의 단독 투여로 발생하는 것으로 알려진 약물이상반응은 이러한 반응이 병용요법을 이용한 임상시험에서 서 보고되지 않았더라도 이들 의약품들을 병용하는 치료 중에 발생할 수 있다. 이 약을 병용 투여할 때는 투여 시작 전에 각각의 병용요법 구성 성분에 대한 허가사항을 참조한다. 이상반응은 기관계 및 빈도별로 나타나 있다. 빈도는 다음과 같이 정의된다: 매우 흔하게 (very common, ≥1/10); 흔하게 (common, ≥1/100~<1/10); 흔하지 않게 (uncommon, ≥1/1,000~<1/100); 드물게 (rare, ≥1/10,000~<1/1,000); 매우 드물게 (very rare, <1/10,000); 빈도 불명(유호 자료에서는 추정할 수 없음). 이 약으로 치료받은 고형암 환자들의 이상반응: 혈액 및 림프계 장애: 단독요법: 매우 흔하게: 빈혈, 흔하지 않게: 자가 면역성 용혈성 빈혈, 내분비 장애:단독요법: 매우 흔하게: 갑상선 저하증, 흔하게: 갑상선 항진증, 부신 부전, 흔하지 않게: 갑상선염, 뇌하수체염, 병용요법: 매우 흔하게: 갑상선 저하증, 흔하게: 갑상선 항진증, 흔하지 않게: 갑상선염, 부신부전: 대사 및 영양 장애: 단독요법: 흔하지 않게: 1형 당뇨병, 당뇨병 케톤산증, 흔하지 않게: 제2형 당뇨병, 신장계 장애:단독요법: 흔하지 않게: 뇌염, 중증 근육 무력증, 병용요법: 흔하지 않게: 근육 무력증 중증; 눈 장애: 단독요법: 흔하지 않게: 포도막염, 병용요법: 흔하지 않게: 포도막염, 심장장애: 병용요법: 흔하지 않게: 심근경색, 호흡기, 흉곽 및 종격 장애:단독요법: 흔하게:폐렴, 병용요법: 흔하게: 폐렴, 위장관 장애: 단독요법: 매우 흔하게: 설사, 오심, 구토, 흔하게: 결장염, 헤장염, 위염, 흔하지 않게: 식도염, 병용요법: 흔하게: 결장염, 헤장염, 위염, 흔하지 않게: 면역-매개 위염, 위장관 혈관염, 간담도 장애: 단독요법: 흔하게: 간염, 피부 및 피하 조직 장애: 단독요법: 매우 흔하게: 발진, 소양증, 병용요법: 매우 흔하게: 발진, 건성 피부, 근골격 및 결합 조직 장애: 단독요법: 흔하게: 근육통, 흔하지 않게: 면역-매개 관절염, 류마티스성 다발 근육통, 면역-매개 근육염, 병용요법: 흔하지 않게: 면역-매개 관절염, 근육염, 신장 및 요로 장애: 단독요법: 흔하지 않게: 신장염, 전신 장애 및 투여 부위 병태: 단독요법: 매우 흔하게: 발열, 흔하게: 오한 병용요법: 매우 흔하게: 발열, 흔하지 않게: 전신성 열증 반응 중증; 임상 검사: 단독요법: 매우 흔하게: 아미노 전이 효소 증가, 병용요법: 매우 흔하게: 알라닌 아미노전이효소 증가, 아스파르트산 아미노전이효소 증가; 손상, 중독 및 시술 합병증: 단독요법: 흔하게: 주입 관련 반응, 2) 면역원성 GARNET 임상에서 이 약을 단독요법으로 투여한 환자 384명에서 항-약물 항체(ADA)를 검사하였고, 이 약 투여로 나타난 ADA 생성률은 21%였다. 중화항체는 환자의 10%에서 검출되었다. 화학요법과의 병용 투여는 이 약의 면역원성에 영향을 미치지 않았다. RUBY 임상에서 화학요법과 병용하여 이 약을 투여받았고 ADA의 존재를 평가할 수 있었던 225명의 환자 중, 이 약 투여로 나타난 ADA 또는 투여로 나타난 중화 항체가 생성된 경우는 없었다. 항-도스타리맵 항체를 생성한 환자에서 이 약의 약동학적 특성, 유효성이나 안전성에 영향을 주지 않았다.

의약품상세정보

젬퍼리주 (도스타리맵)



처방하기 전 QR 코드 또는 식품의약품안전처 의약품통합정보시스템 (https://medrug.mfds.go.kr)을 통해 상세제품정보를 참조하시기 바랍니다.

## ALL IN JEMPERLI

for your ALL advanced/recurrent  
EC patientsThe Advanced or Recurrent  
endometrial cancer treatment option - **Jemperli**

- ⊗ The Immunotherapy **Approved as 1L Treatment** in Combination with carboplatin and paclitaxel, **for primary EC patients regardless of biomarker status<sup>1</sup>**
- ⊗ The 1st Immunotherapy **Approved and Reimbursed for 2L and beyond treatment for dMMR/MSI-H EC patients in Korea<sup>1-4</sup>**



## Efficacy of Jemperli in RUBY trial

- in patients with advanced(stage III, IV) or recurrent endometrial cancer<sup>1,5</sup>In the Overall EC  
population

(Jemperli+CP vs Placebo+CP)

Median  
OS

44.6 vs 28.2 mon

(HR, 0.69; 95% CI, 0.54-0.89;  
stratified log-rank  $P=0.0020$ )

16.4 mon

Reduced risk  
of death

31%

In the dMMR/MSI-H EC  
population

(Jemperli+CP vs Placebo+CP)

Median  
OS

NR vs 31.4 mon

(HR, 0.32; 95% CI, 0.17-0.63; NA)

Reduced risk  
of death

68%

EC, endometrial cancer; dMMR, mismatch repair deficient; MSI-H, microsatellite instability-high; CP, carboplatin & paclitaxel; OS, overall survival; PFS, progression free survival; HR, hazard ratio; CI, confidence interval; NR, not reached.

**RUBY study design<sup>5</sup>:** A total of 494 patients with primary advanced stage III or IV or first recurrent endometrial cancer were included in this phase 3, global, double-blind, randomized, placebo-controlled trial. Patients were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years. The primary end points were progression-free survival(PFS) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors(RECIST), version 1.1, and overall survival(OS).

**Reference:** 1. MFDS. JEMPERLI Prescribing Information. 2. Ministry of health and welfare Notice No. 2023-220. Effective date: Dec 1, 2023. 3. Health Insurance Review and Assessment Organization. Details on the criteria and methodology for coverage of drugs prescribed and administered to cancer patients. Revision date: Sep 2022. 4. Health Insurance Review and Assessment Organization. Details on the criteria and methodology for coverage of drugs prescribed and administered to cancer patients. Revision date: Mar 2022. 5. Powell MA, et al. Ann Oncol. 2024;S0923-7534(24)00721-X.

**Safety Information** 사용상의주의사항 1. 다음 환자에는 신중히 투여할 것. 이 약 및 그 구성 성분에 과민증인 환자 2. 이상사례 1) 임상시험에서 보고된 악물이상반응 GARNET 임상에서 재발성 또는 진행성 자궁내막암 또는 기타 고형 종양이 있는 605명의 환자를 대상으로 단독요법으로서 이 약의 안전성을 평가하였다. 환자들은 4주 동안 매 3주마다 이 약 500mg 용량을 투여받고 나서 이후 매 6주마다 1000mg을 투여받았다. RUBY 임상에서 새로 진단된 진행성 또는 재발성 자궁내막암 환자 241명을 대상으로 화학요법과의 병용요법으로서 이 약의 안전성을 평가하였다. 환자들은 6주 동안 매 3주마다 이 약 500mg 용량을 투여받고 나서 이후 매 6주마다 1000mg을 투여받았다. GARNET 임상에서 이 약을 단독요법으로 투여한 환자와 RUBY 임상에서 화학요법과 병용하여 이 약을 투여받은 환자에서 관찰된 이상반응을 열거하였다. 다양한 유형의 항암 요법과 병용하여 이 약을 투여받은 고형암 환자를 대상으로 실시한 다른 임상시험에서 확인된 추가적인 이상반응 또한 포함되어 있다. 이 약 또는 병용요법 구성 성분의 단독 투여로 발생하는 것으로 알려진 악물이상반응은 이러한 반응이 병용요법을 이용한 임상시험에서 서 보고되지 않았더라도 이들 의약품은 병용하는 치료 중에 발생할 수 있다. 이 약을 병용 투여할 때는 투여 시작 전에 각각의 병용요법 구성 성분에 대한 허가사항을 참조한다. 이상반응은 기관계 및 빈도별로 나타나 있다. 빈도별 다음과 같이 정의된다: 매우 흔하게 (very common,  $\geq 1/10$ ); 흔하게 (common,  $\geq 1/100 \sim < 1/10$ ); 흔하지 않게 (uncommon,  $\geq 1/1,000 \sim < 1/100$ ); 드물게 (rare,  $\geq 1/10,000 \sim < 1/1,000$ ); 매우 드물게 (very rare,  $< 1/10,000$ ); 빈도 불명(유효 자료에서는 추정할 수 없음). 이 약으로 치료받은 고형암 환자들의 이상반응: 혈액 및 림프계 장애- 단독요법: 매우 흔하게 빈혈, 흔하지 않게 자가 면역성 용혈성 빈혈, 내분비 장애-단독요법: 매우 흔하게 갑상선 저하증, 흔하게 갑상선 항진증, 부신 부전, 흔하지 않게 갑상선염, 뇌하수체염, 병용요법: 매우 흔하게 갑상선 저하증, 흔하게 갑상선 항진증, 흔하지 않게 갑상선염, 부신부전, 대사 및 영양 장애- 단독요법: 흔하지 않게 1형 당뇨병, 당뇨병 케톤산증, 흔하지 않게 제1형 당뇨병, 신장계 장애-단독요법: 흔하지 않게 뇌염, 중증 근육 무력증, 병용요법: 흔하지 않게 근육 무력 증후군, 눈 장애- 단독요법: 흔하지 않게 포도막염, 병용요법: 흔하지 않게 포도막염, 심장장애- 병용요법: 흔하지 않게 심근염, 호흡기, 흉막 및 종격 장애-단독요법: 흔하게 폐렴증, 병용요법: 흔하게 폐렴증, 위장관 장애- 단독요법: 매우 흔하게 설사, 오심, 구토, 흔하게 결장염, 위염, 흔하지 않게 식도염, 병용요법: 흔하게 결장염, 흔하게 위염, 흔하지 않게 면역 매개 위염, 위장관 혈관염, 간담도 장애- 단독요법: 흔하게 간염, 피부 및 피하 조직 장애- 단독요법: 매우 흔하게 발진, 소양증, 병용요법: 매우 흔하게 발진, 전신 장애 및 피부 부위 병태- 단독요법: 매우 흔하게 발열, 흔하게 오한 병용요법: 매우 흔하게 발열, 흔하지 않게 전신성 열증 반응 증후군, 임상 검사- 단독요법: 매우 흔하게 이리노 전이 효소 증가, 병용요법: 매우 흔하게 알라닌 아미노전 효소 증가, 아스파르트산 아미노전이효소 증가, 손상, 중독 및 시술 합병증- 단독요법: 흔하게 주입 관련 반응, 2) 면역원성. GARNET 임상에서 이 약을 단독요법으로 투여한 환자 384명에서 항-악물 항체(ADA)를 검사하였고, 이 약 투여로 나타난 ADA 생성률은 21%였다. 중화항체는 환자의 10%에서 검출되었다. 화학요법과의 병용 투여는 이 약의 면역원성에 영향을 미치지 않았다. RUBY 임상에서 화학요법과 병용하여 이 약을 투여받았고 ADA의 존재를 평가할 수 있었던 225명의 환자 중, 이 약 투여로 나타난 ADA 또는 투여로 나타난 중화 항체가 생성된 환자는 없었다. 항-도스타리마브 항체를 생성한 환자에서 이 약의 약동학적 특성, 유효성이나 안전성에 영향을 주지 않았다.

## Product Information

Jemperli  
(dostarlimab)

Learn more about  
Jemperli with  
QR code or at  
<https://nedrug.mfds.go.kr>  
before prescribing.



# Original Bevacizumab

## Proven efficacy in 7 cancer types<sup>1</sup>



 **AVASTIN<sup>®</sup>**  
bevacizumab

품목허가권자



(주)한국로슈 서울특별시 서초구 서초대로 411, GT Tower(East) 빌딩 17층 (06615) Tel 02.3451.3600 / <https://roche.co.kr/>

판매원



에이치케이이노엔(주) 충청북도 청주시 흥덕구 오송읍 오송생명2로 239 Tel 080-700-8802 [www.inno-n.com](http://www.inno-n.com)

Reference : 1. 아바스틴 식약처 허가사항

\*보다 자세한 제품정보 문의 및 제품 관련 부작용 보고는 (주)한국로슈 (02-3451-3600) 로 연락 주시기 바랍니다 \*아바스틴의 최신의 제품정보는 QR code를 스캔하여 확인하실 수 있습니다






# Avastin : The Power of Proof<sup>1-8</sup>

**Avastin in the only original bevacizumab with Phase 3 data [GOG-0213] supporting long-term efficacy and safety in RPS OC.**<sup>10-11</sup>

**Avastin plus chemotherapy significantly improved OS, PFS, and ORR in RPS OC patients.**<sup>11</sup>

**Overall Survival\***  
GOG-0213 Primary Endpoint



**Adverse Events Related to Bevacizumab Treatment**  
GOG-0213

Adverse Event, n (%)	Chemo n=327	Bevacizumab + Chemo n=330
Any adverse event of special interest	75 (23)	237 (72)
Grade 3-5	25 (8)	98 (30)
Serious	19 (6)	49 (15)
Bleeding (CNS)	2 (1)	1 (<1)
Bleeding (non-CNS)*	36 (11)	137 (42)
Congestive heart failure	0	1 (<1)
Fistula or abscess (non-gastrointestinal), grade 3/4	0	0
Gastrointestinal perforations	1 (<1)	6 (2)
Hypertension	10 (3)	135 (41)
Grade 3†	2 (1)	39 (12)
Neutropenia and associated complications (eg, infections)	26 (8)	40 (12)
Grade 3/4	14 (4)	23 (7)
Posterior reversible encephalopathy syndrome	0	0
Proteinuria	3 (1)	56 (17)
Grade 3/4	0	27 (8)
Secondary primary malignancies	1 (<1)	0
Thromboembolic event (arterial)	6 (2)	22 (7)
Thromboembolic event (venous)	0	0
Wound healing complication	2 (1)	10 (3)

Adverse events shown are for all grades unless otherwise stated. \*The most frequent events of non-CNS bleeding (all grades) were epistaxis [109 (33%) in Avastin + Chemo group vs 6 (2%) in Chemo group], contusion [13 (4%) vs 10 (3%)], and rectal hemorrhage [10 (6%) vs 6 (2%)]. †No grade 4 hypertension events occurred. CNS=Central nervous system

HR: hazard ratio, OS: overall survival, RPS: Recurrent Platinum-Sensitive, OC: Ovarian Cancer, PFS: Progression Free Survival, ORR: Objective Response Rate

\*A post-hoc sensitivity analysis using the actual platinum-free interval calculated from the electronic case-report forms. This exercise adjusted the HR for death slightly to 0.823 [95% CI 0.680 - 0.996; p=0.0447]. The estimated effect on overall survival in the prespecified subgroups was consistent with the primary analysis.

**GOG-0213 Study Design:** The multicenter, open-label, randomized phase 3 trial in 67 predominantly academic centers. Eligible patients were adult women (Aged 18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer and clinical complete response to primary platinum-based chemotherapy who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly allocated to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m<sup>2</sup> of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab [15mg/kg of bodyweight] every 3 weeks. And continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was overall survival, analyzed by intention to treat.

**PFS:** Median progression-free survival was significantly longer with the addition of bevacizumab versus chemotherapy alone [10.4 months [95% CI 9.7 - 11.0] with chemotherapy alone vs 13.8 months [13.0 - 14.7] with chemotherapy plus bevacizumab; adjusted HR for surgery and treatment-free interval for progression or death 0.628 [95% CI 0.534 - 0.739], p<0.0001]

**ORR:** An exploratory post-hoc analysis of investigator assessed objective response [complete or partial response according to RECIST version 1.1] was done for the 509 (76%) patients with measurable disease in whom serial imaging was available to assess response. A significantly higher proportion of these patients achieved objective response in the chemotherapy plus bevacizumab group [196 (78%) of 249 patients] compared with the chemotherapy group [152 (59%) of 260 patients; p<0.0001]

**Reference :** 1. Hurvitz H, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004;350(23):2335-2342. 2. Sandler A, et al. Paclitaxel + Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med. 2006;355(24):2542-2550. 3. Miller K, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med. 2007;357(26):2666-2676. 4. Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111. 5. Friedman H, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740. 6. Burger RA, et al. Incorporation of Bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483. 7. Tewari KS, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med. 2014;370(8):734-743. 8. NCCN Guideline Version 3.2024 Ovarian Cancer. 9. 의학물안전나라 의학물통합정보시스템. (Accessed on 21 Jan 2025. Available from: <https://nedrug.mfds.go.kr>) 10. 식품의약품안전처 의학물통합정보시스템. <https://nedrug.mfds.go.kr/searchDrug?sort=&sortOrder=false&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemName=&itemEngName=&entpName=&entpEngName=&ingName1=&EB%82%A0%EB%80%94%EC%A3%BC%EB%A7%99&ingName2=&ingName3=&ingEngName=&itemSeq=&strCodeName=&atcCodeName=&industryClassCode=&ssClassNo=&narcoidGndCode=&cancelCode=&etcOtcCode=&makeMaterialGo=&searchConfe=AN&eeDocData=&searchConId=AND&udDocData=&searchConId=AND&ndDocData=&startPmtDate=&endPmtDate=> (Accessed on 21 Jan 2025) 11. Coleman RL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779-791.

\*Scan the QR code for the latest product information of Avastin.

수입원

**Roche**

(주)한국로슈 서울특별시 서초구 서초대로 411 GT Tower(East) 빌딩 17층 (06615) Tel 02.3451.3600 / <https://roche.co.kr/>

판매원

**inno.N**

에이치케이이노엔(주) 충청북도 청주시 흥덕구 오송읍 오송생명2로 239 Tel 080-700-8802 [www.inno-n.com](http://www.inno-n.com)





# LONGER mPFS, BETTER SURVIVAL<sup>1-5</sup>

- ZEJULA<sup>®</sup> can be taken regardless of other drugs or food, which helps improve patient adherence to medication.<sup>6,7</sup>
- ZEJULA<sup>®</sup> is the only PARP inhibitor covered by insurance in Korea as the 1L monotherapy in the HRd/BRCAwt & BRCAmut ovarian cancer population.<sup>6,8,\*</sup> (Copayment 5% by insurance coverage from Oct 2024)

\*As of Mar 2025  
**References** 1. González-Martín A *et al.* Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2019;381:2391-402 & Supplementary Appendix 2. González-Martín A *et al.* Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed advanced ovarian cancer. *Eur J Cancer* 2023 Aug;189:112908. & Supplementary material. 3. Monk BJ, *et al.* Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. *Ann Oncol* 2024 Nov;35(11):981-992 & supplementary 4. Ning Li, *et al.* Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2023;9(9):1230-1237 & Supplementary material. 5. Zhu J, *et al.* Impact of dose modifications due to treatment-emergent adverse events (TEAEs) on the efficacy of niraparib maintenance treatment with an individualized starting dose in patients (Pis) with newly diagnosed advanced ovarian cancer (aOC). #198. Presented at SGO Annual meeting on women's cancer 2023, Tampa, Florida, 25-28 Mar 2023. 6. ZEJULA<sup>®</sup> Prescribing Information. <https://medrug.mfds.go.kr/pbp/CBB0001/getitemdetail?itenSeq=20190726> Accessed in Mar 2025 7. Friedlander M, *et al.* Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data. *Am Soc Clin Oncol Educ Book* 2023 Jun; 43:e390876. 8. Notification No. 2024-129, Insurance review & assessment service, (oct on Oct 1, 2024)



한국다케다제약(주) 서울특별시 송파구 올림픽로 300 롯데월드타워 37층 대표번호 02-3484-0800  
 \* 제품관련 의학정보(학술)문의 Tel : 080-908-0971 / E-mail : medinfoAPAC@takeda.com \* 이상사례보고 AE.SouthKorea@takeda.com  
 Copyright © 2025 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited, used under license. All trademarks are the property of their respective owners. The information on this material is intended for healthcare professionals only.  
 C-APROM/KR/NIR/0861 Date of Preparation: Mar/2025



제줄라<sup>®</sup> 제품 정보  
 QR코드를 통해 제줄라<sup>®</sup>의 제품 정보 전문을  
 확인하실 수 있습니다.





# 1st choice for 2nd line of Ovarian cancer<sup>1</sup>

[illegible]**Baxter**

본사 : 서울특별시 서대문구 충정로 8 (충정로 3가)  
 공장 : 충남 천안시 서북구 선거로 망향로 797-48  
 소비자상담실 : 080-6776-080(수신자 부담)



중근당


CLX CKD 202207 272(Expire:202408)

# Cervical Disease Risk identified with greater confidence

## CINtec PLUS cytology


- \* Reflected in the 2024 ASCCP guidelines as a triage test for HPV positive cases <sup>1)</sup>
- \* FDA-approved testing demonstrated by large-scale prospective clinical studies (IMPACT trial) <sup>2)</sup>

### 01 Used to triage abnormal PAP cytology screening results




ASC-US: atypical squamous cells of undetermined significance ;  
LSIL: low-grade intraepithelial lesion; HSIL: high-grade intraepithelial lesion

### 02 Used to triage 12 other hrHPV positive results



### 03 Used to triage PAP negative/ HPV positive co-testing results





# HPV 관련 암 예방 가다실<sup>9</sup>로 기적을 열다!



**다양한 암 예방 가능<sup>1,\*</sup>**  
(자궁경부암, 외음부암, 질암, 항문암)

**10년간 확인된  
Long-Term Data  
보유<sup>2,a,#</sup>**

**약 97%의  
암 및 병변 예방 효과<sup>3,b,†</sup>**

HPV : Human papillomavirus, LTFU : Long-term follow-up

\* 가다실 9은 만 9~45세 여아 및 여성에서 HPV 16, 18, 31, 33, 45, 52, 58형에 의한 자궁경부암, 외음부암, 질암, 항문암 및 만 9~26세 남아 및 남성에서 HPV 16, 18, 31, 33, 45, 52, 58형에 의한 항문암 예방에 적용증을 허가받았습니다.<sup>1,\*</sup> [Main outcome] Immunogenicity : >94% participants were seropositive at month 126 (based on HPV-9 IgG-LIA).  
Effectiveness : There were no cases of high grade dysplasia or condyloma related to vaccine-targeted HPV 11, 16, 18, 31, 33, 45, 52, 58. Safety : No vaccine-related SAEs were reported during LTFU through 10 years postvaccination.<sup>1</sup> 5가지 HPV 31, 33, 45, 52, 58형과 연관된 고등급 질암 : 자궁경부암, 외음부암, 질암 및 전암 병변(자궁 경부 상피내 종양 2/3기, 외음부 상피내 종양 2/3기, 질 상피내 종양 2/3기, 자궁경부 상피내 신양), PPE : 95% confidence interval 80.9-99.8. ※ 다른 백신과 마찬가지로, 이 백신을 접종 받은 모든 피검종자가 면역, 예방 효과를 나타내는 것은 아닙니다.

Study design a. Girls and boys who received 3 doses of 9vHPV vaccine in the base study were eligible for the LTFU study to evaluate immunogenicity, effectiveness, and safety through month 126 (10 years postdose 3). The primary objective of the LTFU study was to evaluate anti-HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 antibody responses through 10 years postdose 3. This study was conducted from August 27, 2009 (first participant visit in the base study) through April 22, 2021 (last participant, last visit in the LTFU study). Of 2,553 boys and girls who received 3 doses in the base study, 1,272 consented to participate and 922 (72.5%) completed the study.<sup>1</sup> b. A randomized, international, multicenter, double-blind study that included a total of 14,215 women (GARDASIL 9+7, 109) who were enrolled and vaccinated without prescreening for the presence of HPV infection, was conducted to evaluate the immunogenicity, efficacy, and side-effect profile of the 9vHPV vaccine in women 16 to 26 years of age. Swabs of labial, vulvar, perineal, perianal, endo-cervical, and ectocervical tissue and Pap test samples were collected on day 1 and at months 7, 12, 18, 24, 30, 36, 42, 48, and 54. The primary efficacy evaluation was based on a composite clinical endpoint of HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, invasive cervical carcinoma, high-grade vulvar intraepithelial neoplasia, high-grade vaginal intraepithelial neoplasia, vulvar cancer, and vaginal cancer.<sup>3</sup>

Reference 1. 가다실 9 제품 허가사항, 식품약품안전처 2. Restrepo J, et al. Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. Pediatrics. 2023;152(4):e2022060993. 3. Joura EA, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med. 2015;372:711-23.

**가다실<sup>9</sup> 주요 안전성 정보 (Selected Safety Information) [사용상의 주의사항]** 1. 다음 환자에게는 투여하지 말 것. 이 백신이나 가다실 또는 각 백신의 성분과 관련된 사람 (이 백신이나 가다실 접종 후 관련종양이 나타나는 경우 추가 접종하지 않는다) 2. 다음 환자에는 신중히 투여할 것. 1) 현재 또는 최근 영성 질환이 있는 자 (종양의 중증도와 병변에 따라 백신 접종을 계속 진행할 것인지, 보류할 것인지 결정한다. 일반적으로 마비 및 경련이 상기도 감염은 백신 접종에 금기사항이 아니다.) 2) 저혈소판증이나 기타 혈액응고장애가 있는 환자 (이 백신 근육주사 시 출혈이 있을 수 있으므로 주의해야 한다.) [이상사례] 모든 연령과 성별에서 이 백신과 가다실은 다양한 이상은 유사하였다. 모든 임상시험의 이 백신 투여군에서 발현율이 1.0% 이상으로 보고된 백신관련 주사부위 및 전신 이상사례 : 통증, 부기, 홍반, 가려움증, 발열, 두통, 발진, 오심, 이질감, 피로 등 [일반적 주의] 1) 다른 백신과 마찬가지로 이 백신을 접종받은 모든 피검종자가 면역, 예방 효과를 나타내는 것은 아니다. 2) 이 백신은 진행 중인 외부 생식기 병변, 자궁경부암, 외음부암, 질암, 항문암, 자궁경부 상피내 종양, 외음부 상피내 종양, 질 상피내 종양, 항문 상피내 종양의 치료를 대상으로 하지 않는다. 3) 이 백신은 인유두종바이러스(Human Papillomavirus, HPV)에 의한 것이 아닌 질병은 예방하지 않으며, 백신에 포함되어 있지 않은 HPV 유형에 의한 질병에 대해서도 예방하지 않는다. 4) 다른 주사용 백신과 마찬가지로 백신 투여 후 드물게 알레르기 반응이 나타나는 경우 적절한 처치가 즉시 이루어져야 한다. 5) 면역억제제의 사용, 유전적 결함, 사람 면역결핍바이러스(HIV) 감염 또는 기타의 원인에 의해 면역 반응이 저해되어 있는 경우 백신 접종에 의한 항체 반응이 감소될 수 있다. 개정일 : 2024년 1월 11일

※ 처방하기 전에 더 자세한 내용은 제품설명서를 참고하시기 바랍니다. ※ 오른쪽 QR 코드를 스캔하실 경우 MSD의 사이트가 아닌 외부 사이트로 이동합니다. MSD는 해당 사이트에서 제공하는 콘텐츠에 대해 책임 지지 않습니다. 제품을 원하실 경우 QR 코드를 스캔하시기 바랍니다.



# KSGO

## International Conference 2025

The 40th Annual Meeting of  
Korean Society of Gynecologic Oncology



Korean Society of Gynecologic Oncology

KSGO International Conference 2025 Secretariat:  DoubleYou

Address. 7, Achiul-gil 22beon-gil, Guri-si, Gyeonggi-do, Republic of Korea Tel : +82-2-6959-5624 | Fax : +82-2-6959-9379 | E-mail : ksgo2025secretariat@gmail.com

Korean Society of Gynecologic Oncology

Address. 36 Gangnam-daero 132-gil, Gangnam District, Seoul, Republic of Korea Tel. +82-2-512-5915, 0044 | Email. gyncancer@gyncancer.or.kr

President, Jae-Kwan Lee | Business license number: 211-82-60962